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Foreword
It is with great pleasure that I present the eighth General report of activities of the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The report provides a retrospective 
account of the EMCDDA’s activities and accomplishments during 2002. 
Four main axes of work were defined in the 2001–2003 work programme, namely: monitoring 
the situation of drug use, monitoring the responses to drug use, implementing the EU joint action 
on new synthetic drugs and monitoring national and Community strategies and their impact. 
These areas are supported by the Reitox network of national focal points and enlargement 
activities as well as dissemination and administrative initiatives. 
In 2002, a major focus was the promotion in the Member States of the key indicators used to 
monitor the drug situation, as well as the conceptualisation and development of new indicators 
in the policy relevant areas of drugs and crime, social exclusion and drug availability. Significant 
progress was made on the objective to establish core data sets in the area of responses to 
drug use through the development of standard tables. This should enhance the level of EU 
comparability in this area for the years to come. The Centre’s risk-assessment work on new 
synthetic drugs remained high on the political agenda with the decision by the Council to place 
PMMA under control and the launch of risk-assessment exercise for four new drugs – TMA-2, 
2C-I, 2C-T-2 and 2C-T-7. Profound reflection on the scientific tools and methods to be used for 
monitoring and evaluating national strategies in the drugs field has been initiated with internal 
and external cooperation. The EMCDDA’s participation in the evaluation of the EU action plan on 
drugs resulted in the publication of Baseline 1999 – the first of two snapshots, which shows the 
situation and responses in place prior to the adoption of the plan. The EMCDDA also contributed 
to the Commission’s communication on the mid-term evaluation of the plan.
Intensive work was carried out with the Reitox network on preparing a new operating framework 
and financing system. Priority was also awarded to preparing the candidate countries for 
participation to the EMCDDA’s activities; the Reitox Academy was set up, a curriculum developed, 
training modules prepared and training activities executed and evaluated.
Efforts to increase and improve communication with policymakers were stepped up – in 
particular with the introduction of a series of synthesised policy briefings entitled Drugs in focus 
covering topics such as recreational drug use, substitution treatment, prevention in schools and 
drug injecting. The 2002 Annual report on the state of the drugs problem in the European 
Union and Norway was launched at the European Parliament along with the very first Report 
on the drug situation in the candidate CEECs, the latter signalling a major step forward for the 
EMCDDA.
The expanse of activities carried out by the Centre are described in detail in the pages that follow. 
We have created this new online format to facilitate consultation of the results achieved and we 
hope it will prove to be a useful resource. I take this opportunity to thank all those who contributed 
to the Centre’s achievements in 2002.
Georges Estievenart
Executive Director
Foreword
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Work programmes
2001–2003 work programme
The 2001–2003 work programme focuses on:
•  monitoring the drug situation; 
•  monitoring responses to the drug problem; 
•  implementing the 1997 joint action on new synthetic drugs; and
•  monitoring national and Community strategies and policies and their impact on the drug 
situation. 
These activities are supported by dissemination and administrative initiatives and by the Reitox 
network of national focal points. Special attention is also paid to EU enlargement, in accordance 
with the ‘Enlargement strategy’ adopted by the Board in September 2000.
The work programme is consistent with the targets of the EU action plan on drugs (2000–2004) 
with special attention paid to the tasks for which the plan calls upon the EMCDDA for action. 
Its orientations reflect the reform plan through the implementation of activity-based management/
budgeting and a project-based approach.
The architecture of the work programme is summarised in two tables: 
•  a thematic matrix (see page 11), which provides an overview of the core structure of the 
work programme showing the links between the EMCDDA’s main working areas (monitoring 
the situation, responses and impact) and the strategy targets of the EU action plan on drugs 
(2000–2004). 
•  a  summary of the priority working areas (see page 12), which illustrates the working priorities 
and the role of the EMCDDA and its respective partners in each task. 
2002 work programme
The 2002 work programme defines the projects to be undertaken in the various thematic 
areas outlined in the 2001–2003 work programme and continues to implement the goals and 
objectives set out within it.
A budget (43KB) of € 9 412 500 was adopted for the implementation of the 2002 work 
programme. Of this, 33% of the resources were earmarked for monitoring the drug situation; 
28% for monitoring responses; 15% for the Reitox network; 15% for monitoring strategies and 
their impact; and 9% for implementing the joint action on new synthetic drugs.
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Thematic matrix of the 2002 work programme
EU target P1 — Monitoring of the situation P2 — Monitoring of the responses
T1
Reduce prevalence of illicit drug 
use, as well as new recruitment, 
especially among young people
Drug use in general population (ki)
Prevalence of problematic drug 
use (ki)
Emerging trends (cd)
Primary prevention (cd)
Outreach work in recreational 
settings (cd)
T2
Reduce incidence of drug-related 
health damage and drug-related 
deaths
Drug-related infectious disease (ki) 
Drug-related deaths and mortality 
(ki)
Prevention of drug-related 
infectious diseases (cd)
Prevention of heroin overdose (cd)
Users’ rooms (cd)
T3
Increase number of successfully 
treated addicts
Demand for treatment (ki) Availability of treatment facilities (cd)
T5
Reduce drug-related crime
Drug-related petty crime (cd)
Drug-related social exclusion (cd))
Prevention of drug-related
crime (cd)
Social rehabilitation and 
reintegration (cd)
T4
Reduce availability of illicit drugs
Global availability of illicit drugs 
(cd)
Availability of illicit drugs at street 
level (cd)
Interdiction measures (cd)
T6
Reduce money laundering and illicit 
trafficking of precursors
Drug-related financial flows (cd)
Flow of diverted chemical 
precursors (cd)
Anti money laundering
measures (cd)
Measures against the diversion of 
chemical precursors (cd)
P3 — Implementing the EU JA on new synthetic drugs: early warning system and risk assessment 
Monitoring situation and responses concerning NSD (cd)
National and Community strategies
and policies
(T1, T2, T3, T4, T5, T6)
EU action plan 2000–2004
P4 — Monitoring national and Community strategies and policies and 
their impact on the drug situation
National and community strategies
and policies (cd)
Implementation of the EU action 
plan on drugs 2000–2004 (pi)
ki = key indicators cd = core data pi = performance indicators
Italic and grey font indicate where the EMCDDA acts as a secondary producer, collecting and disseminating
the information from other relevant European and international partners who are the primary producers.
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Work programmes
Priority working aereas
EMCDDA
added value
EMCDDA 
3 working 
priorities
EMCDDA
compulsory 
6 priority areas
Data collection and 
comparative analysis of 
the drug situation in the 
EU and its MS
Data collection and 
comparative analysis of 
responses in the EU and 
its MS 
Establishing tools for the 
analysis of the impact of 
responses in the EU and 
its MS
EMCDDA: 
primary information 
producer in the EU
(1) Demand and 
reduction of demand * * Implementing 
the 5 harmonised 
epidemiological key 
indicators
* Developing social core 
data
Developing and testing 
a core data set on 
demand reduction
Analysis of the impact 
of demand reduction on 
the drug situation
(2) National and 
Community strategies 
and policies *
—
Developing and testing 
a core data set on
* international, bilateral 
and Community policies
* action plans
* legislation
* activities and 
agreements
Analysis of the impact of 
international, bilateral 
and Community 
strategies on the drug 
situation
EMCDDA: secondary 
information 
producer in the 
EU, in partnership 
with European 
and international 
organisations
(3) International 
cooperation and 
geopolitics of supply *
Supporting the 
development and testing 
of a core data set on 
producer and transit 
countries (UNDCP, 
INTERPOL, EUROPOL, 
WCO,UNDCP)
Supporting the 
development and testing 
of a core data set on 
producer on
* cooperation 
programmes
(UNDCP, WHO, CICAD, 
EC)
Analysis of the impact 
of international 
cooperation
(4) Control of trade  
in narcotic drugs, 
psychotropic substances 
and precursors *
Supporting the 
development and testing 
of a core data set on 
law enforcement
(EC, EUROPOL, WCO, 
INTERPOL, UNDCP)
Supporting the 
development and 
testing of a core data 
set on action against 
trafficking
 (EC, EUROPOL, WCO, 
INTERPOL, UNDCP)
Analysis of the impact of 
law enforcement
(5) Implications of the 
drugs phenomenon for 
producer, consumer 
and transit countries 
(including money 
laundering) *
Supporting the 
development and testing 
of a core data set on
* market
* illicit financial flows
(EC, FATF, UNDCP)
Supporting the 
development and testing 
of a core data set on 
antimoney laundering 
instruments and 
cooperation
(EC, FATF, UNDCP)
Analysis of the impact 
of anti laundering 
measures
EMCDDA: 
Primary information 
producer in 
partnership with 
Europol and EU 
organisations
(6) Joint action of 
16 June 1997 on 
New synthetic drugs 
** (‘Early Warning 
System’)
Rapid collection 
and exchange of 
informationon New 
synthetic drugs
Risk assessment, 
assessment of health 
and social consequences 
of New synthetic drugs
Assessment for the 
preparation of control 
measures to be 
implemented in MS;
monitoring of these 
measures once taken
EMCDDA: 
primary information 
producer in the EU
(3) International 
cooperation and 
geopolitics of supply *
Global synthesis on the 
drug situation in the EU 
and its MS
Global synthesis on the 
drug situation in the EU 
and its MS
Analysis of the impact of 
global responses on the 
global drug situation in 
the EU and its MS
* According to EMCDDA Regulation of 8 February 1993
** According to the Joint action of 16 June 1997 on New synthetic drugs
 15  1
 15  1
Chapter 1
Programmes, projects and transversal activities
Monitoring the drug situation 
(Situation analysis, programme P1)
The objective of this programme is to provide a scientific description and analysis of the drug 
situation in the EU that is reliable, comparable and relevant to the needs of policy formation. The 
specific aims of the programme are to: 
•  provide an overview of the drug situation in the EU based on collection and analysis of the best 
available data on drug use, supply and their health and social consequences and correlates;
•  improve the comparability and quality of data on prevalence and health consequences through 
the implementation in Member States of five harmonised epidemiological indicators and 
through the development at EU level of structures and mechanisms to collect, validate, analyse 
and disseminate data;
•  identify and conceptualise potential indicators of social consequences and correlates of drug 
use and supply;
•  analyse and interpret the significance of quantitative and qualitative data on trends and 
differences in prevalence, patterns and consequences of drug use, and  assess implications for 
public health and social policies on drugs;
•  enhance the analytical insights that are provided by the data by placing them in a broader EU 
level context; 
•  collaborate with other projects, national focal points, Community bodies and programmes and 
other European and international bodies; and
•  disseminate results that are reliable and useful for decision-makers, scientists and professionals 
at Community and national levels.
Overview of progress achieved during 2002
Epidemiological data from national reports and other sources were analysed and synthesised, 
for dissemination in a number of technical, policy orientated and scientific reports and papers. A 
comprehensive synthesis of epidemiological data was prepared for the EMCDDA’s 2002 Annual 
report. 
•  Chapter 1 described and compared prevalence, characteristics and trends in drug use and its 
major health consequences, as well as law-enforcement data and indicators of drug supply 
and availability. 
•  Chapter 3 contained special issues on polydrug use and drug use in prison. 
•  Complementary statistical tables containing standard core data from the Member States were 
compiled and made available online.
Chapter 1
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Data for the EMCDDA’s 2003 Annual report were collected from the national focal points, and 
the process of validation and synthesis begun.
Improving data comparability and quality
A major focus has been the promotion of the implementation of the five key harmonised 
indicators of drug prevalence and health consequences, formally adopted in September 2001 
by Member States (1). In addition, attention has continued to be directed at the conceptualisation 
and development of new indicators in the policy relevant areas of drugs and crime, social 
exclusion and drug availability.
Five key epidemiological indicators
A range of activities were carried out in partnership with Member States to continue supporting 
the implementation of the five key indicators. Achievements in this area are clearly reflected in 
improvements in both the quantity and quality of data reported to EMCDDA using the standard 
reporting formats. Specific activities conducted during 2002 included:
•  continued coordination, monitoring and feedback on progress of implementation by Member 
States, including the organisation of EU-level expert groups;
•  continued development of central epidemiological databases and electronic infrastructures for 
collecting, analysing and disseminating data, including developing the architecture for specific 
key indicator databases under the EISDD umbrella. Enhanced rules and mechanisms for 
validity checking, archiving and data management were introduced and key tables expanded 
to cover routinely collected crime data;
•  discussions to identify synergies with Eurostat and Sanco (DG Public Health – health 
monitoring) continued; and 
•  work on guidelines for reporting on key indicators. Progress made in 2002 includes: the 
development of complementary guidelines (ICD-10) for reporting on drug-related deaths (in 
partnership with Eurostat and WHO), and their integration in a revised protocol, and the 
further refinement of guidelines on the reporting of drug-related infectious diseases.
Development of core data on social indicators
Work continued on conceptualising potential indicators and core data in new areas of the 
EMCDDA’s work programme, involving collaboration with Europol and other partners.
•  Drug-related crime: Work on the conceptualisation of this area continued and a draft 
definition of drug-related crime was identified, as explicitly requested in the EU action plan. 
The Information Maps on data sources from law enforcement agencies and the criminal justice 
system were analysed. Data on drug-law offences and drug users in prison were collected and 
analysed. 
•  Drug-related social exclusion: Work continued on developing a conceptual framework for 
exploring the relationship between drug use and social exclusion, special attention was given 
to drug use among ethnic minority groups and a report prepared on this issue. 
•  Availability of illicit drugs: Data on drug markets and drug availability were collected and 
analysed. Model questions in the area of drug availability were drafted.
(1) The five indicators are: extent and patterns of drug use in the general population; prevalence of problem drug use; demand for treatment by 
drug users; drug-related deaths and mortality of drug users; and drug-related infectious diseases.
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Analysis and interpretation: qualitative and quantitative
Emerging trends and QED
Work on emerging trends in drug use and drug problems continued to review and develop 
‘leading-edge’ indicators, with particular emphasis on the analysis of youth media. Work 
was undertaken on the conceptualisation of a theoretical framework to explain and if possible 
anticipate how drug use trends develop and become problematic. 
The project also contributed epidemiological and sociological information for the joint action 
on new synthetic drugs. The QED website (Qualitative European Drug Research Network), a 
tool for networking researchers and exchanging information on qualitative research on patterns 
and trends in drug use and related behaviours, especially amongst youth, was evaluated (using 
quantitative and qualitative methods).
TSER modelling network
This network was based on funding from the European Commission’s targeted socio-economic 
research programme (TSER) until the end of 2002. A final report on the Centre’s work with 
research networks of modellers on prevalence and incidence methodology, geographical and 
temporal diffusion of drug use, economic modelling and social costs and cost-effectiveness was 
issued.
Cooperation
Cooperation with other European and international bodies included: UNDCP for the streamlining 
of international reporting (ARQ); the Pompidou Group for the treatment demand indicator; WHO 
for the drug-related deaths indicator; the Drugs Coordination Unit at the European Commission 
for the legal basis and coordination; Eurostat for the indicators on drug-related deaths and 
prevalence of drug use in the general population (surveys); DG Public Health (Sanco) for the 
health monitoring programme; EuroHIV for the drug-related infectious diseases indicator; Europol 
for drug-related crime, availability, seizures; the ESPAD project for prevalence in the general 
school population and Enlargement in preparation for progressive participation of candidate 
countries in the activities of the EMCDDA.
Projects
The different areas covered by the Situation analysis programme are separated into projects and 
are under the responsibility of a project manager.
Prevalence and patterns of drug use among the general population
Objectives 
•  To promote and coordinate the implementation of the key indicator by Member States
•  To produce an EU overview of drug use among the general population
•  To complete the first version of the EMCDDA databank on population surveys and conduct a 
selected initial joint analysis on the databank   
Activities
A Handbook on population surveys was published. It is based on EMCDDA guidelines for the key 
indicator and on information collated during the previous projects that developed the guidelines. 
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An annual expert meeting on population surveys, with the 15 Member States, Norway and 
Poland and with Eurostat participation was held.
An assessment was made of progress of implementation in the Member States with information 
collected in detailed questionnaires.
Information reported by countries through standard Reitox tables was collected and analysed. 
Information was incorporated into the EISDD (Epidemiological Info System on Drug Data) 
database and used to draft the section in the Annual report on the prevalence of drug use.
The procedures for setting up the first version of the EMCDDA databank of population surveys 
were completed, national databases were harmonised and a joint database created and 
transferred to the EMCDDA (with assistance of the contractor and of the EISDD project manager). 
An initial joint analysis of the databank was carried out on selected topics – the incidence of 
cannabis use and the gender gap in drug use. 
The project manager also collaborated on the Madrid seminar for candidate countries organised 
by EMCDDA Enlargement Unit and contributed to the assessment of EU action plan on drugs 
(Snapshot – Baseline 1999).
Outputs
•  EMCDDA Handbook on population surveys based on key indicator guidelines
•  Minutes of the expert meeting on the key indicator prevalence of drug use among general 
population
•  Results of national questionnaires on the implementation of the key indicator and summary 
analysis
•  2002 Annual report: section on drug use among the general population and related standard 
tables 
•  Revised project report (CT.00.EP.14) with summary of databank implementation process and 
joint analysis results
For further information on this project see: 
http://www.emcdda.eu.int/situation/themes/drug_use_general_population.shtml
Prevalence and patterns of problem drug use
Objectives
•  To promote the implementation of the key indicator in the Member States
•  To analyse and report existing data, focusing on policy questions
•  To disseminate results to the scientific community and to policy makers
•  To collaborate with international organisations
Activities
Data was collected and checked. The data provided by the Member States according to 
EMCDDA guidelines were entered. The text and statistical tables for the Annual report were 
produced.
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The final report on project CT.00.RTX.23 was co-produced with the contractor IFT, Germany. 
The final report ‘TSER European Drug Modelling Network’ was produced. This was the 
culmination of a three-year project funded by DG Research, Targeted Socio-Economic Research, 
involving six working groups and over 40 researchers. As a follow-up to this TSER project, an 
expression of interest was submitted to DG Research for the European Network: European Drugs 
Modelling Network, with IMIM, Barcelona.
Contributions were made to policy briefings and the EU action plan, Snapshot-Baseline 1999. 
Press interviews were given and presentations made at high level visits to EMCDDA. Input was 
provided for EISDD database development and data processing.
The project manager participated in the programme committee of the International Conference 
on the Reduction of Drug-related Harm and organised and chaired four sessions on quantitative 
approaches to drugs research, based on the results of the TSER project (modelling, economic 
costs, initiation of IDU, incidence estimation).
The project manager also collaborated with international organisations and key European 
players (UNDCP, UNAIDS, WHO, NIDA/GRN, EuroHIV, European Prison Network) regarding 
estimation of IDU population sizes/prevalence.
Outputs
•  2002 Annual report: general section on problem drug use and online statistical tables 
•  Concise overview of implementation of the key indicator
•  Final report project CT.00.RTX.23 by contractor IFT, Germany 
•  Revised standard data reporting tables for local and national level prevalence estimates and 
updated guidelines for national reports including integration of UNDCP/ARQ items
•  Final report ‘TSER European Drug Modelling Network’ (three-year project funded by DG 
Research, Targeted Socio-Economic Research, involving six working groups and over 40 
researchers)
•  Contribution to Drugs in focus issues 1, 3 and 4 on injecting drug use, prevalence and 
incidence and substitution treatment
•  Baseline 1999 snapshot data for the evaluation of the EU action plan 
•  Press coverage and interviews at launch of 2002 Annual report
•  Expression of interest for European Network: European Drugs Modelling Network (follow-up of 
TSER), with IMIM, Barcelona 
•  Scientific article on prevalence estimates accepted in Addiction (Kraus et al.), EMCDDA co-
authorship
•  Four sessions on quantitative approaches to drugs research (modelling, economic costs, 
initiation of IDU, incidence estimation), based on results TSER project, at the 2002 International 
Conference on the Reduction of Drug-related Harm, Ljubljana
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Drug treatment demand
Objectives
•  To promote the implementation of the treatment demand indicator in the Member States
•  To produce a basic overview based on existing data, focusing on policy questions
•  To collect and check a full data set from Member States, integrating it into the epidemiological 
database
•  To collaborate with international organisations
Activities
Data provided by the Member States according to the Treatment Demand Indicator (TDI) Protocol 
was collected, checked and entered in the database. 
A steering group meeting took place on data quality and analysis. The annual expert meeting 
on treatment demand, involving 15 Member States and Bulgaria was held. The EMCDDA 
participated in the Pompidou Group working group on treatment demand (May and December 
2002).
A training seminar on treatment demand was run for the candidate countries in Utrecht, 
in March. Data on treatment demand were presented at national conferences (Italy and 
Netherlands) and meetings with international organisations (CICAS, ONDCP, SAMHSA, 
UNDCP).
Outputs
•  2002 Annual report: general section on treatment demand and treatment demand data on 
polydrug use 
•  Documents for the training seminar for candidate countries
•  Minutes of steering group, expert meeting, meeting with international organisations
•  Contribution to Drugs in focus policy briefing on injecting drug use
•  Slides and poster (Nijmegen) for conferences attended
For further information on this project see:
http://www.emcdda.eu.int/situation/themes/demand_treatment.shtml
Drug-related infectious diseases
Objectives
•  To promote the implementation of the key indicator in the Member States
•  To analyse and report existing data, focusing on policy questions
•  To disseminate results to the scientific community and policy makers
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•  To collaborate with international organisations
Activities
Data was collected and checked. The data provided by the Member States according to 
EMCDDA guidelines were entered and contributions to the development of the EISDD database 
and data processing were made. Text and statistical tables for the 2002 Annual report were 
produced.
A training seminar for accession countries on infectious diseases was organised in Madrid. 
Exchange and discussion of protocols for local seroprevalence studies with focal points and 
experts took place.
Contributions were made to policy briefings, Baseline 1999 (EU action plan snapshot exercise, 
articles in Drugnet, press interviews and presentations at high level visits to EMCDDA). National 
expert groups were animated via email correspondence and meetings. 
Two expressions of interest for European Networks were submitted to DG Research: 1) hepatitis C 
and liver cancer, 2) surveillance of HIV, HCV, TB in IDUs.
The EMCDDA Scientific Monograph no 7, ‘Injecting drug use and hepatitis C: impact, costs 
and policy options’ (Jager et al. eds, available in 2003) was edited and two chapters – on 
‘epidemiology’ and ‘policy options’ – were written.
The programme manager participated in programme committees of two international scientific 
conferences (International AIDS conference, International Harm Reduction conference). EMCDDA 
infectious diseases data were presented at three international scientific conferences (International 
AIDS conference, International Hepatitis conference and International Harm Reduction 
conference).
Presentations were made at three international expert workshops (WHO hepatitis C expert 
consultation, Geneva; WHO/UNAIDS/UNDCP global reference group on HIV prevention in 
IDUs, Vienna; European network on HIV/AIDS and hepatitis prevention in prisons, Budapest).
Collaboration continued with international organisations and key European players: UNDCP, 
UNAIDS, WHO, NIDA/GRN, EuroHIV, European Prison Network.
Outputs
•  2002 Annual report: general section on Infectious diseases and online statistical tables on HIV, 
hepatitis B and C in IDUs 
•  Concise overview of implementation of the key indicator infectious diseases
•  Meeting report November 2001 European expert meeting with full abstracts of all 
presentations and updated minimum reporting requirements/guidelines
•  Revised standard data reporting table in joint collaboration with EuroHIV and updated 
guidelines for national reports including integration UNDCP/ARQ items
•  Presentation on key indicator at Madrid training seminar for accession countries 
•  Contribution to Drugs in focus policy briefing no 4 on ‘Injecting drug use’ 
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•  1999 baseline snapshot data for evaluation EU action plan 
•  Press release and TV/radio interviews on World Drugs Day regarding HIV/AIDS
which were picked up by CNN world 
•  Two expressions of interest at DG Research for European Expert Networks: 
1) hepatitis C and liver cancer, 2) surveillance of HIV, HCV, TB in IDUs
•  Abstract submitted, poster produced and orally presented at the International AIDS conference. 
Press coverage included CDC prevention-news (US Atlanta). A major session on HIV prevention 
was also chaired at this conference.
•  Participation in International AIDS conference programme committee, epidemiology track, and 
responsibility for four sessions on HIV and IDU 
•  Participation in 2002 International Harm Reduction Conference programme committee; 
organisation and chairing of a session on economic costs of drug use; co-authorship of 
presentation on costs of IDU-related hepatitis and HIV
•  Two abstracts submitted for 2003 International Harm Reduction Conference on 1) HIV and IDU 
2) coverage of interventions, 
•  Literature review on hepatitis C in IDUs in the EU accepted in scientific journal (Roy et al, 
Epidemiology and Infection)
•  Analysis of EMCDDA data on hepatitis C in IDUs submitted to scientific journal (Wiessing et al)
•  Analysis of coverage of needle exchange in the EU submitted on invitation to special issue in 
International Journal on Drug Policy (Wiessing and Hedrich)
•  Chapter on epidemiology of hepatitis C submitted to scientific monograph (Wiessing et al)
•  Three chapters submitted as co-author to scientific monograph no 7: conceptual model of the 
drugs field (Jager et al), simulation modelling of hepatitis C dynamics (Kretzschmar et al), 
economic impact of hepatitis C (Postma et al)
Drug-related deaths and mortality among drug users
Objectives 
•  To promote and coordinate the implementation of the key indicator by Member States
•  To produce an EU overview of drug-related deaths and mortality among drug users 
Activities
The guidelines for ICD-10 based on general mortality registries were developed and tested (with 
assistance of contractors). A small expert meeting (core group) including the contractor, WHO 
and Eurostat was held to develop the guidelines.
The annual expert meeting on drug-related deaths took place with the participation of the 15 
Member States and Norway. 
A comprehensive and updated protocol for the drug-related deaths key indicator was produced, 
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incorporating ICD-10 guidelines and with improved procedures for extraction, selection and 
reporting of cases. 
An assessment of national progress on the drug-related deaths indicator was made using a 
national questionnaire.
A new version of the Reitox data collection instruments for drug-related deaths, which integrate 
national and EMCDDA standard definitions, were developed and implemented. Content of 
previous project reports on mortality among drug users was integrated into a new standard table 
for Reitox data collection.
An EU overview of drug-related deaths and mortality among drug users was produced and a 
contribution to the assessment of the EU action plan on drugs (snapshot) was made.
The project manager collaborated on the Madrid Seminar for candidate countries, organised by 
EMCDDA Enlargement team.
Outputs
•  Project report on the development and testing of guidelines for ICD-10 based general mortality 
registries.
•  Minutes of core expert group on the drug-related deaths key indicator
•  New version of the EMCDDA protocol for the drug-related deaths key indicator  (version 3).
•  Results of national questionnaires on the implementation of the drug-related deaths key 
indicator
•  Revised report based on projects CT.99.EP.07 and CT.00.EP.13
•  2002 Annual report: section on drug-related deaths and mortality and related standard tables 
For further information on this project see:
http://www.emcdda.eu.int/situation/themes/death_mortality.shtml
Drug trends in youth
Objectives 
•  To describe and analyse drug use among youth, especially under 18 years, in the framework of 
target 1 of the EU action plan
•  To collect data on drugs used, patterns of use, trends, characteristics and initiation to drugs 
among young people 
•  To develop a theoretical framework for interpreting and predicting drug trends 
•  To carry out a contextual analysis of drug trends in youth
Activities
Quantitative and qualitative data were collected and analysed for the Annual report, the selected 
issue on polydrug use and for the Drugs in focus policy briefings.
An expert meeting for early conceptualisation of a framework for predicting trends in youth was 
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held (internal report). The development of a new instrument for user perspective and a pilot study 
were initiated by expert group (internal working paper).
Early exploration of comparable indicators for vulnerable youth was initiated and a youth media 
voluntary project is in progress (internal working paper).
The project collaborated with ESPAD for data on 15/16-year-old school students.
Outputs
•  Text and tables for Annual report 
•  Selected issue on polydrug use 
•  Policy briefing on recreational drug use 
•  Improved guidelines for Reitox national focal points
•  Presentation at international conference on nightlife substance use and related health issues
For further information on this project see:
http://www.emcdda.eu.int/situation/themes/youth_trends.shtml
QED – European Qualitative Drug Research network and website
Objectives
•  To maintain and increase the utility of http://qed.emcdda.eu.int, within the framework of the 
medium term perspectives of the Centre (adopted by the Management Board in September 
2000) 
•  To disseminate information to practitioners and researchers working in the drugs field
Activities
Information was sought and collected from drug researchers in the EU and disseminated 
electronically on an ongoing basis. Newsletters in all EU languages were produced and mailed.
Outputs
•  Continuous dissemination (of updated material)  – over 700 bibliographic references, 430 
researchers, over 100 recent and current projects plus 15 Member State profiles and other 
website areas
•  Average statistics of 5000 visitor sessions per month and over 20% visiting more than once
•  Evaluation of QED (using quantitative and qualitative methods)
•  Newsletters in all EU languages and Drugnet articles
•  Evaluation of QED (using quantitative and qualitative methods)
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For further information see: http://qed.emcdda.eu.int/ 
Drug-related crime
Objectives
•  To analyse law enforcement information sources on ‘arrests’, seizures, drug use among 
arrestees/prisoners
•  To analyse drug law offences data
•  To analyse existing information on drug users in prison
•  To review definitions, data availability and possible indicators of crime related to drug use and 
drug users, notably juvenile and urban delinquency
•  To contribute to the evaluation of the EU action plan (2000–2004)
Activities
The Information Maps on law-enforcement sources 2000–2001 were analysed and a final report 
(3 volumes) drawn up, after validation by the national focal points.
Drug law offences data and related information were extracted, verified and analysed from the 
national reports and standard tables of the EU Member States and Norway. Texts were written 
and tables and graphs generated for the Annual report.
Data on the demand and supply of drug use in prison were extracted, verified and analysed 
from the national reports and standard tables of the EU Member States and Norway. Texts were 
written, a comprehensive table on proportions of drug users in prison across the EU prepared 
and graphs drawn for a selected issue within the Annual report.
A study to ‘Review definitions, data availability and possible indicators of crime related to drug 
use and drug users, notably juvenile and urban delinquency’ was carried out on behalf of the 
EMCDDA by the Midlands Centre for Criminology, Loughborough University, UK, from October 
2001 to November 2002.
An expert meeting to review definitions of drug-related crime and existing potential indicators 
was organised. A draft working definition was adopted.
Data were provided to be included in Baseline 1999 of the first snapshot exercise to evaluate 
target 5 of the EU action plan on drugs (2000–2004).
Outputs
•  Internal working papers on the conceptualisation of drug-related crime and potential indicators
•  EMCDDA scientific report ‘Drug seizures, drug offences, drug offenders, drug use among 
criminal populations – Information systems based on law enforcement agencies and the 
criminal justice system’ (3 volumes)
•  EMCDDA scientific report ‘Review of definitions, data availability and possible indicators of 
crime related to drug use and drug users, notably juvenile and urban delinquency’
•  Contributions to the 2002 Annual report and statistical tables 
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•  Contributions to Baseline 1999 snapshot exercise (target 5)
For further information on this project see:
http://www.emcdda.eu.int/situation/themes/crime.shtml
Social exclusion
Objectives
•  To analyse drug use, consequences and correlates amongst minorities
Activities
A study to update and complete the analysis of drug use, consequences and correlates amongst 
Black and minority ethnic groups in the EU and Norway was carried out on behalf of the 
EMCDDA by the Centre for Ethnicity and Health, University of Central Lancashire, UK, from 
December 2001 to October 2002. Results were based on the answers to a questionnaire specific 
to each country and addressed to key informants.
Several working documents on drug-related social exclusion were gathered to produce an 
internal working paper.
Outputs
•  Internal working paper on drug-related social exclusion in the context of socio-demographic 
and economic indicators
•  EMCDDA scientific report on ‘Drug use, consequences and correlates amongst minorities’
For further information on this project see
 http://www.emcdda.eu.int/situation/themes/social_exclusion.shtml
Drug availability
Objectives
•  To develop a standard module of questions on drug availability to include in population surveys 
questionnaires
•  To analyse drug seizures, price and purity and existing data on drug availability and drug 
markets from the national focal points
•  To contribute to the evaluation of EU action plan (2000–2004)
Activities
An expert group was formed and a meeting organised in order to review questions on drug 
availability within population surveys and agree upon a strategy to develop a standard module 
of questions on drug availability to include in the EMQ (European Model Questionnaire). The 
mapping of existing questions included within adult and school surveys was completed and 
validation through cross-tabulations of questions carried out by some of the experts.
The conceptualisation of drug availability and potential indicators was taken further. A strategy 
on activities to be carried out was devised for 2002–2004. 
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Data on drug seizures, price, purity, contents of tablets and other drug market-related 
information were extracted, verified and analysed from the national reports and standard tables 
of the EU Member States and Norway. Texts were written and tables and graphs generated for 
the Annual report.
Data were provided for inclusion in Baseline 1999 of the first snapshot exercise to evaluate target 
4 of the EU action plan on drugs (2000–2004).
Outputs
•  Internal working paper on ‘Availability of illicit drugs: concepts, potential indicators, 
information sources, and perspectives 2002–2004’ 
•  Internal report on developing a module of questions on drug availability within the EMQ
•  Contributions to the 2002 Annual report and statistical tables  
•  Contributions to Baseline 1999 snapshot exercise (target 4) 
For further information on this project see:
http://www.emcdda.eu.int/situation/themes/availability.shtml
EMCDDA Epidemiological Info System on Drug Data – ‘EISDD’
(Database support for implementation of the key indicators) 
Objectives
•  To introduce telematics into drug epidemiology i.e. using telecommunications facilities in 
combination with informatics in order to improve data management (collecting, archiving, 
retrieval and analysis of epidemiological information)
•  To develop the EISDD indicator-related database
•  To create a data dictionary – to make an internal translation of commonly used codes in all 
databases
•  To collect data online – pilot project for aggregated data on drug prevalence surveys in the 
general population
•  To carry out data analysis – producing subsets from specific indicator-related databases for 
statistical elaboration
Activities
After the MetaDatabase of the EISDD became fully operational at the end of 2001, the main 
developmental activities in 2002 concentrated on the creation of seven specific, key indicator-
related database systems under the common EISDD umbrella. Thus, the entire architecture 
was shaped in the first quarter of 2002 and then, during the rest of the year the programming 
activities concentrated first on the creation of the relevant data structures for standard tables 
01–09, including the complex structures of the treatment demand indicator, version 2.0.
For the prevalence on drug use among the general population and for direct drug-related 
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death data from the national general mortality registers and the national forensic registers, 
two additional database subsets were included into the main system to host more specific 
epidemiological micro data on the one hand and more specific but aggregated death data 
according to EMCDDA expert guidelines, on the other.
Since September 2002, appropriate working platforms were programmed and tested to assist 
new staff in the management of archiving and checking of data from the 2002 collection. It was 
also in the third quarter of 2002, that a concise user manual for data archiving, data checking 
and further data management became available to the staff working on the project. At the end of 
2002, the pilot project ‘online data collection’ commenced with the setting up of an appropriate 
interface between the EMCDDA IT department and EISDD.
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Monitoring responses to drug use 
(Responses analysis, programme P2)
Overview of main achievements
P2 prepared the ‘Responses to drug use’ chapter of the EMCDDA 2002 Annual report and was 
substantially involved in all three selected issues: Polydrug use, Successful treatment, and Drug 
use in prisons. Three of the Drugs in focus policy briefings have been coordinated by P2: Drug 
prevention in schools, Drugs and recreational settings, Drug treatment in prisons, and the team 
also contributed to the policy briefing on Drug injecting. Several reports were published on the 
EMCDDA website: Guidelines for the evaluation of outreach work, Assistance to drug users in 
prisons, Treatment availability, Availability of social reintegration interventions, Survey of school-
based prevention in the EU, as well as several thematic EDDRA analyses.
The objective to develop standard tables to establish core data sets for all areas of responses 
to drug use (set in the 2001—2003 triennial work programme) has been achieved. The project 
managers have developed the standard tables (with the exception of supply reduction) in 
cooperation with external experts in the respective areas, representatives of national focal points 
and, in most cases, representatives of the Scientific Committee. Data requirements focus on 
indicators of service availability, completed by (or to be completed by) indicators of intervention 
quality. They will be included in the national reporting requirements from 2003 onwards. At the 
same time, the national reporting guidelines have been modified in order to balance text and 
tables.
EDDRA has been subject to an internal evaluation, which has pointed out the relevance of the 
information system as a source of information about best practice both among national focal 
points and in the practice field in Member States. Improvements in utility and visibility have been 
suggested. However, the insertion of new EDDRA projects has been low, probably mainly due to 
resources lacking in focal points. On the other hand, several analyses of EDDRA contents (school 
prevention, risk reduction, treatment, prisons, women) reveal the potential of EDDRA in policy 
and practice development.
The team contributed to the Baseline 1999 snapshot exercise for the evaluation of the EU action 
plan (2000-2004) and assisted in the drafting of the mid-term Commission evaluation report.  An 
analysis of national strategies and achievement of objectives is underway and awaiting the latest 
input from the 2002 national reports.
In cooperation with the Impact and strategies analysis team, a procedure for the accreditation of 
European drug-related NGOs in a European Transnational Networks on Drugs (ETND) has been 
established and a call for expressions of interest is ready to be launched.
Topic-specific collaboration with the institutional partners UNDCP, WHO and the Pompidou 
group has continued during the year, as well as specific contacts with Europol, Interpol, and 
WCO in the field of supply reduction. P2 co-sponsored the ENDSP (European Network for Drug 
Services in Prisons) conference ‘Engaging with Change’ (without financial implications) and 
participated actively in many other conferences and meetings at European and national levels.
Representatives of candidate countries participated in several expert meetings. The Reitox 
Academy seminar on demand reduction in June in Riga embarked on a very intensive review 
of all areas of P2 responses on the basis of candidate countries´ national reports. The seminar 
ranked very highly among the Reitox Academy seminars in the participants´ rating and it was 
also successful from the staff point of view.
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Projects 
The different areas covered by the responses area are divided into project areas and are under 
the responsibility of a project manager.
Prevention responses
Objectives 
•  To develop common core data on prevention intensity in the Member States
•  To improve information on implementation trends of prevention policy in practice and the 
coverage of problem areas
•  To obtain agreement on a set of quality models and approaches for school/community 
prevention programmes
•  To obtain agreement on a set of criteria to evaluate school/community prevention quality
•  To develop methods for estimating school/community prevention-related costs
•  To relate drug school/community prevention with other social problems (housing, education, 
violence)
•  To increase the number of prevention evaluation instruments in the European Instruments Bank 
(EIB)
Activities
For the 2002 Annual report, online tables were drafted on the basis of information from the 
national reports. They give a first comparative overview of prevention activities in the EU and 
Norway, according to a range of variables and also list relevant web-based resources. The 
material collected allowed the policy briefing Drugs in focus issue number 5 ‘Drug prevention 
in EU schools’, to be compiled which summarises positive experiences and points out deficits in 
prevention policy and practice in the EU.
At an expert seminar in September 2002, the reports and analyses on prevention available to 
that date were presented and the simplification of reporting tools for Member States discussed. 
The standard tables on the extent and content of school-based prevention have been simplified 
and improved in cooperation with Member States. 
An analysis of survey questionnaires sent out in 2001 to school-based prevention programmes 
in Member States provided a good insight into school-based prevention programmes, their 
theoretical background, operating mode and internal coherence. A training module based on 
the survey analysis was developed. It defines prevention quality and the coherence between 
intervention models and respective evaluation indicators. A first training session with 150 
prevention professionals was carried out in Greece in October 2002.
Extensive work was invested in assuring quality control of new EDDRA entries. 
During the Reitox Academy seminar in Riga, representatives of candidate countries were trained 
in standardised reporting according to key variables for National reports, standard tables and 
for EDDRA.
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Outputs
•  Standard tables on prevention in schools and kindergartens
•  Online table 7OL in the Annual report.
•  Drugs in focus no 5 ‘Drug prevention in EU schools’
•  Report on the analysis of Survey questionnaires on school-based prevention (from 2001)
•  Report on the analysis of Survey questionnaires on community-based prevention (from 2001)
•  Burkhart, G., ‘Políticas Europeas: posibilidades y límites’. In Vega, A. (ed.): Drogas – qué 
políticas para qué prevención, pp. 105-129. Gakoa Liburuak. San Sebastián 2002
•  Burkhart, G., ‘Una revisión de los programas escolares Europeos recogidos por el sistema de 
información EDDRA’. IDEA prevención, N° 23, Julio/Diciembre 2001, Pp. 64-74
•  Burkhart, G., ‘Favorire la valutazione. Perché occorrono delle linee guida per la valutazione?’  
In: Baraldi, C., Coletti, M. (Eds): Linee guida per la valutazione della prevenzione delle 
tossicodipendenze. Franco Angeli, Milano 2001, pp. 22.28.
For further information on this project see:
http://www.emcdda.eu.int/responses/themes/prevention_schools_communities.shtml
Outreach work in recreational settings, including pill-testing interventions
Objectives 
•  To develop drafts for a set of harmonised core data to compare the intensity of outreach work 
in recreational settings in Member States
•  To develop core data on number, coverage, intensity and budgeting of interventions for 
outreach work in recreational settings, including on-site pill testing
•  To compile a set of quality models and approaches for outreach work in recreational settings 
and results, including on-site pill testing
•  To develop a core set of criteria for the effect and performance of outreach work in recreational 
settings
Activities
Online tables for the 2002 Annual report were drafted on the basis of national reports. They give 
a first comparative overview on activities in this field.
Relevant input was given to the policy briefing Drugs in focus number 6 ‘Recreational drug use’, 
especially describing and assessing response measures.
During an expert seminar in September 2002, the reports and analyses on prevention of 
recreational drug use available to that date were presented and the feasibility of introducing 
standardised reporting tools for Member States was discussed. Standard tables to trace the extent 
of outreach work in recreational settings have been improved and finalised in cooperation with 
Member States and will be the information collection tool in 2003. Elements from the safe dance 
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guidelines, available at www.clubhealth.org.uk have been taken into account. 
An analysis of EDDRA programmes on prevention in recreational settings has been performed 
and it provided input to the expert meeting. Extensive work was invested in assuring quality 
control of new EDDRA entries. 
An analysis of survey questionnaires sent out in 2001 gave an indicative overview of outreach 
work projects in some of the Member States.
During the Reitox Academy seminar in Riga, representatives in candidate countries were trained 
in standardised reporting according to key variables for national reports, standard tables and for 
EDDRA.
Outputs
•  Standard tables on prevention in recreational settings
•  Online table 7OL in the Annual report
•  Drugs in focus number 6 ‘Recreational drug use’ 
•  Report of the analysis of EDDRA projects on prevention in recreational settings
•  Report of the analysis of survey questionnaires on outreach work (from 2001)
•  Burkhart, G., ‘Análisis de Pastillas in situ’. Adicciones, Vol. 14, n° 3, 2002, pp. 293-301
•  Burkhart, G. (ed): ‘Demand reduction activities in the field of synthetic drugs in the European 
Union’. In: Calafat, A et al.: Risk and control in the recreational drug culture. IREFREA, 2001 
(www.irefrea.org)
For further information on this project see:
http://www.emcdda.eu.int/responses/themes/outreach_needle_exchange.shtml
Prevention of drug-related infectious diseases
Objectives 
•  To analyse information on approaches (policies and interventions) to the prevention of 
infectious diseases among IDUs contained in the national reports available
•  To analyse data on provision, utilisation and coverage of specific harm reduction measures 
(based on standard table 10)
•  To identify possible core data on the prevention of infectious diseases among IDUs
•  To discuss a draft core-data set and develop it further through the expert group meeting
•  To discuss and define objectives and tasks for work on a core data set for the comprehensive 
monitoring of infectious disease prevention measures
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Activities 
Data collection on harm reduction measures to prevent infectious diseases in injecting drug users 
(standard table 10) was continued and the online tables were updated. Textual information from 
the 2001 national reports was summarised in the respective chapter of the Annual report with a 
focus on main trends in policies and practice in the prevention of infectious diseases among drug 
users. 
The tool for the collection of core data on harm reduction measures to prevent infectious diseases 
among IDUs (standard table 10) was amended by adding more structured reply options and 
refining information collection on hepatitis C prevention. 
Preparatory work was carried out for a major review of the standard table in 2003 with 
regard to a) its comprehensiveness for monitoring infectious disease prevention measures, b) its 
adequacy and usefulness for candidate countries, as well as c) its sensitivity to changing drug 
use/injecting patterns and related risks.  
Outputs
•  Section in 2002 Annual report  and updated online tables 8 and 9: ‘Provision and types 
of needle/syringe exchange programmes, pharmacy involvement and numbers of syringes 
exchanged’; ‘Provision of HIV counselling and testing, HIV treatment and HBV vaccination for 
injecting drug users’ 2002 Annual report:
•  Contribution to EMCDDA policy briefing Drugs in focus, issue no 4 (July–August 2002): ‘Drug 
injecting challenges public health policy’ 
•  Refinement of standard table for the national reporting exercise 2003 
•  Hedrich, D., Nikolov, Z., Subata, E. (2002) ‘HIV/AIDS prevention among injecting drug users: 
Key issues in central/eastern Europe’. Paper presented at 13th International Harm Reduction 
Conference, Ljubljana.
Prevention of heroin overdose
Objectives
•  To draft a first overview of approaches (interventions/policies) and promising practice in the 
EU in heroin overdose prevention
•  To identify a possible core-data set on heroin overdose prevention (standard table) that can 
contribute to the evaluation of the EU action plan (2000–2004)
Activities
Project work started in April 2002 and included the collection and analysis of literature on 
the prevention of drug-related deaths – in particular on opioid overdose prevention and 
management – and a questionnaire survey among national focal points on policies and 
interventions in overdose prevention and management and on ‘promising practice’ (July to 
September 2002). 
The results of this survey were summarised and fed back to national focal points, and 
cooperation was established with representatives of recommended ‘promising practice’ projects. 
An expert meeting was held on 24 to 25 October 2002 to present ‘promising practice’ and to 
discuss a draft data collection instrument (standard table).
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A standard table on ‘Reduction of drug-related deaths – focus on overdose’ was developed for 
national reporting in 2003. The overview of available information and ‘promising practice’ was 
updated, and areas for future work in the area identified.
Outputs
•  Section in 2002 Annual report
•  Standard table for national reporting on ‘Reduction of drug-related deaths – focus on 
overdose’ finalised for pilot exercise in 2003 
•  Overview of approaches and ‘promising practice’, based on information from national focal 
points, including recommendations for future work in the area
For further information on this project see:
http://www.emcdda.eu.int/responses/themes/overdose_prevention.cfm
Users’ rooms/consumption rooms
Objectives
•  To assess the state of the art, including achievements, challenges and lessons learned with 
regard to consumption rooms 
•  To identify possible core data on consumption rooms
•  To draw up objectives and tasks for work on a core-data set in 2003
Activities
Work on the project started in April 2002 with the collection of published and grey literature on 
consumption rooms – with a focus on evaluation studies. An international group of consultant 
experts from Germany, the Netherlands, Spain, Switzerland and Australia was established.
In consultation with the expert group, an up-to-date bibliography on consumption room studies 
was compiled and a database of key information on consumption rooms created. Work on the 
summary of available evidence on consumption rooms was started. 
An international expert meeting was organised and took place on 23 and 24 September 2002 
to present and discuss selected evaluation studies and consumption room management issues. 
Data sets that are currently used to document consumption room service delivery were identified 
and the need for increased comparability in the collection of operational data and in monitoring 
service implementation confirmed by the expert group. A draft key data set was discussed and a 
work plan for 2003 developed.
Outputs
•  Summary of status quo in consumption rooms in 2002 Annual report
•  Bibliography on consumption rooms
•  Database on consumption rooms
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For further information on this project see:
http://www.emcdda.eu.int/responses/themes/consumption_rooms.cfm
Availability of treatment
Objectives 
•  To provide a first overview of treatment activities and facilities in the EU
•  To develop definitions of and standards for treatment at a European level
•  To develop criteria and instruments to assess treatment quality and effectiveness
•  To provide citizens with up-to-date information on treatment responses to drug use in the EU
•  To expand the number of instruments in the Evaluation Instruments Bank (EIB) and the use of it
Activities
An overview of treatment facilities and availability in the EU was published in April 2002. 
With the assistance of external experts, classification and definitions and standards of treatment 
related to illegal drugs were developed in order to improve the collection of information. Criteria 
and instruments to assess treatment availability as well as its quality and effectiveness were 
developed as standard tables. The standard table on availability of treatment includes treatment 
modality (withdrawal treatment, medically-assisted treatment and drug-free treatment) and setting 
(general practitioners, inpatient and outpatient). The standard table on the quality of treatment 
collects information on guidelines, regulations and monitoring of physical environment, staff 
composition and training, clients rights, inclusion/exclusion criteria, existing treatment plan and 
quality assurance. 
‘Successful treatment’ was a selected issue in the 2002 Annual report and further input to the 
report was provided on the availability of treatment. 
18 new or updated instruments were collected for the EIB, one of which was in a language of an 
accession country, Slovenian. 
Frequent quality controls have been carried out on new EDDRA entries in the area of treatment 
related to illegal drugs. 
At the Reitox Academy seminar in Riga, representatives from candidate countries were trained 
in standardised reporting in the area of treatment according to the key variables for national 
reports and for EDDRA.
Outputs
•  ‘Classifications of drug treatment and social reintegration and their availability in EU 
Member States plus Norway’. (The 95-page web publication was published 2 April and was 
downloaded 2959 times during the course of April – the most downloaded file that month at 
the EMCDDA website. In October it was number six with a total of 934 downloads.) 
•  2002 Annual report treatment availability and selected issue ‘Successful treatment’  
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•  Standard table on treatment availability  
•  Standard table on quality assurance and standards in treatment
•  Analysis of EDDRA entries in the area of treatment 
•  ‘Linee di indirizzo politico e strategie di intervento, in Europa, in materia di 
politossicodipendenza’, an article for an EU-financed publication on polydrug use. Written 
with Linda Montanari, Danilo Ballotta and Deborah Olszewski
•  An overview of opiate substitution treatment and its characteristics in the European Union and 
Norway’, article published in International Journal of Drug Policy in November 2002. Written 
in cooperation with Gregor Burkhart and Margareta Nilson
For further information on this project see:
 http://www.emcdda.eu.int/responses/themes/drug_treatment.shtml
Social rehabilitation and reintegration
Objectives
•  To provide a first overview of social rehabilitation and reintegration activities in the EU
•  To develop definitions of and standards for social rehabilitation and reintegration at a 
European level
•  To develop criteria and instruments to assess the quality and effectiveness of social 
rehabilitation and reintegration
•  To provide citizens with updated information on social reintegration responses to drug use in 
the EU
Activities
A first and preliminary overview on social reintegration facilities and their availability in the EU 
Member States and a chapter on the overall EU situation was produced and published in April 
2002. However, this proved to be difficult in some countries and the task of making an overview 
for these countries was outsourced and a report provided in October 2002. Based on this report 
and the preliminary publication, a new overview chapter on social reintegration was written 
and the country reports were revised. A new website publication on the availability of social 
reintegration was published in December 2002. 
Definitions of and standards for social reintegration were developed in close cooperation with 
the contractor. Criteria to assess the availability of social reintegration were defined. A two-
dimensional standard table was developed, including kind of intervention (education, housing or 
employment), and whether the service is exclusively for illicit drug users or a general service with 
access for other user groups.
Frequent quality control has been carried out on new EDDRA entries in the area of social 
reintegration.
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At the Reitox Academy seminar in Riga, representatives from candidate countries were trained 
in standardised reporting according to key variables for national reports, and for EDDRA in the 
area of social reintegration.
Outputs
•  ‘Classifications of drug treatment and social reintegration and their availability in EU Member 
States plus Norway’. Updated report exclusively on social reintegration published on the 
EMCDDA website in December 2002 
•  Standard table on availability of social reintegration services
For further information on this project see:
http://www.emcdda.eu.int/responses/themes/social_rehabilitation.shtml
Prevention of drug-related crime
Objectives 
•  To produce a snapshot of responses to drug-related crime
•  To analyse national reports and write up section in the Annual report
•  To further develop the prevention of drug-related crime (PDRC) conceptual map
•  To produce a first analysis based on the PDRC conceptual map
Activities
The selected issue on ‘Drug use in prison’ was prepared for the 2002 Annual report. Additional 
online elements were drawn up including tables on prison drug strategies and drug-free and 
substitution treatment in prisons. A policy briefing on drug treatment in prison was also drafted 
for publication in 2003. 
Since the development of a conceptual map on prevention of drug-related crime was not 
successful, the project was modified to focus on interventions in prisons and alternatives to prison.
The guidelines for national reporting were reformulated, the standard table on assistance to drug 
users in prisons expanded and a new table on the alternatives to prison for drug-dependent 
offenders introduced. A seminar refining the core data on alternatives to prison for drug-
dependent offenders was held at the EMCDDA in December.
A protocol to collect data at prison level has been developed internally. A workshop to review the 
protocol and discuss the strategy for data collection was held at the 6th European Conference on 
Drugs and HIV/AIDS services in prison in October organised by ENDSP. 
An analysis on criminal justice based programmes of EDDRA was produced and published on 
the EDDRA website.
At the Reitox Academy seminar in Riga feedback was given to the CEEC focal points on the 
national report chapter ‘Interventions in the criminal justice system’. 
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Outputs
•  Selected issue ‘Drug use in prison’ in the 2002 Annual report
•  Standard table for ‘Assistance to drug users in prisons’ as well for ‘Alternatives to prisons for 
drug dependent offenders’ for national reporting 2003
•  A Protocol on ‘Measures and actions concerning drug users in prisons’ for information 
collection through ENDSP
•  Criminal justice based drug demand and harm reduction interventions in the EU
•  An analysis of the police station, courts and prisons-based programmes contained in EDDRA
•  Policy briefing, Drugs in focus No 7  ‘Drug users in prisons’, produced in collaboration with P1 
and P4
•  Presentations at International Experts Forum 2002 held in Canada in April and the Italian 
conference on drug services in prison in November
•  Mujeres toxicodependientes en la Unión Europea. Acts from the I Siposium Nacional sobre 
Adicción en la mujer. Madrid, October 2000. 
For further information on this project see:
http://www.emcdda.eu.int/responses/themes/prevention_crime.shtml
Exchange on Drug Demand Reduction Action (EDDRA) information system
Objectives 
•  To collect reliable and comparable information on high quality programmes on drug responses
•  To ensure continuous and updated information on ongoing programmes
•  To provide information on methods and implementation as well as on evaluation results
Activities
An internal evaluation survey was conducted among the EDDRA Managers. The survey areas 
covered the main objectives of EDDRA: to be an information instrument, to be an education and 
planning tool (in both cases two thirds considered the objectives fulfilled) and to be a networking 
instrument (one third considered the objective fulfilled). 
A working group formed at the 2001 annual meeting of EDDRA Managers met in June and in 
November. Outputs included a survey on the needs of EDDRA users, which addressed projects in 
EDDRA and projects known to national focal points that are not (yet) included in EDDRA. 
During 2002, several analyses of EDDRA contents (school prevention, risk reduction, treatment, 
prisons, women) threw light on EDDRA’s potential in policy and practice development.
On the technical level, 2002 has been an important step towards a more reliable and efficient 
information system:
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1) a new offline tool to allow a more stable and effective working of the system; 
2) a web editing tool allowing modification of the web pages of the EDDRA site;
3) adaptation of the layout of the EDDRA website;  
4) a new section for ‘further reading’;
5) a tool to adapt the translation of the EDDRA online questionnaire.
By November 2002, 31 projects had been received from national focal points.
Outputs
•  New offline tool with new features
•  New web editing tool
•  New layout in the EDDRA website
•  Several qualitative analyses of EDDRA on specific themes
For further information on this project see:
EMCDDA - Responding to drug use - Methods and tools - EDDRA
Interventions for drug supply reduction
Objectives 
•  To follow up on the process allowing the EMCDDA to extract a selection of data already 
existing in the EU and international partners’ databases
•  To carry out a feasibility study relating to availability of national data in a few Member States
•  To establish a preliminary draft of a possible core data set for all EU Member States
•  To systemise data collection according to the Centre’s priority targets for dissemination
Activities
Two internal EMCDDA reports were produced. The first one relates to the identification of and 
accessibility to information on supply reduction concerning interdiction measures, measures 
against the diversion of chemical products under control, and anti money-laundering measures. 
Accessibility to main information sources in these three fields depends on the implementation of 
an adequate cooperation framework with some of the EMCDDA international partners, such as 
UNDCP, Europol, Council of Europe and World Customs Organization.
The second report relates to available data at national level through two national examples, 
Spain and France. The main sources of information identified relate to Europol, Customs 
authorities, International Narcotic Control Board, National Finance Authorities, and the Financial 
Action Task Force. 
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Thirdly, a preliminary draft of possible core data sets involving all EU Member States was 
submitted, concerning the three different elements of this project.
An EMCDDA internal working party, based on these two reports and the suggested core data 
sets, was devoted to systematising data collection according to the Centre’s priority targets for 
dissemination.
It was finally suggested that, during the course of 2003, three expert working parties should 
establish the basis for general agreement concerning core data on interdiction measures, anti 
money-laundering measures and measures against the diversion of chemical precursors.
Outputs
•  Internal report on identification and accessibility to information on supply reduction
•  Internal report on available data at national level: Spain and France examples
•  Draft core data set on supply reduction for all EU Member States
•  Conclusions of the internal EMCDDA working party on systematic data collection according to 
the Centre’s priority targets for dissemination
•  Contribution to the 2002 Annual report
•  Lecture at Rovira I Virgili University, 3 July 2002, Tarragona
•  Lecture at Complutense University, 3 September 2002, Madrid
•  Submission of a lecture to Friedrich-Ebert-Stiftung, 15 October 2002, Berlin
For further information on this project see:
http://www.emcdda.eu.int/responses/themes/supply_reduction.shtml
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Implementing the EU joint action on new synthetic drugs 
(programme P3)
Overview of main achievements
In 2002, the activities of the joint action on new synthetic drugs focused on two main aspects: on 
the one hand, the management of the Early Warning System (EWS), including carrying out an 
overview of all new substances detected on the EU market; on the other hand, the improvement of 
the EWS through the second EWS workshop with the participation of all relevant partners.
Since the adoption of the joint action in June 1997 and the setting-up of the EWS, a certain 
number of synthetic substances have been detected and monitored. Depending on different 
variables such as the gravity of the consequences (deaths), the nature of evidences (overdoses), 
the frequency of findings (not anecdotal), the scope of the presence in the market (notifications 
and seizures), the EMCDDA and  Europol: a) have produced joint reports for some of these 
substances, when the initial estimation of risks required it; b) have continued to collect information 
for the others, with less evident risks, in order to complete the picture with the new findings.
On the basis of the EMCDDA-Europol joint reports, the EMCDDA’s extended Scientific Committee 
has been requested to carry out the risk assessment of these substances. Thus, risk-assessment 
reports have been produced for the substances MBDB, 4-MTA, GHB, ketamine, PMMA. Following 
these risk-assessment exercises, and according to the procedures, decisions were taken to put 
under control some of these substances (4-MTA, PMMA) and to continue to monitor the others 
(MBDB, GHB, ketamine) for which no sufficient evidence was available to put them under control. 
In the meantime, the EMCDDA and Europol have obtained more information on a series of 
substances with different levels of evidence and danger, which were reported to the Horizontal 
Working Party on Drugs of the Council of the European Union in October 2002. 
Furthermore, following the experience of the first EWS workshop, a second one was organised 
in November 2002 in order to continue to improve of the EWS by analysing legal and 
administrative matters related to implementing the mechanism. This workshop was organised 
with the aim of analysing the scope of these matters and reaching a consensus on possible 
solutions. Prior to the workshop, the EU and candidate country focal points were consulted via a 
questionnaire on different aspects of implementation.
Projects
Objectives 
•  To rapidly collect and exchange information on new synthetic drugs (NSD) through the EWS 
(art. 3 JA; permanent task)
•  To strengthen the Reitox networking capacity in the EWS and the EMCDDA coordination role 
for data collection and processing, monitoring and feedback
•  To set up an EMCDDA information system on synthetic drugs
•  To carry out risk assessments of new synthetic drugs (art. 4 JA; permanent task)
•  To introduce a preparatory phase for involving candidate countries in the JA (art. 3 and 4) in 
the framework of the pre-accession strategy
General report of activities 2002
42  
Chapter 1
 43  
Activities
Article 3 JA
This involves the permanent collection, analysis and exchange of information on synthetic drugs 
(PMA, MDMA, 2C-B, ‘Yaba’, illicit use of medicinal substances being sold as ‘ecstasy’) and on 
new synthetic drugs (TMA-2, 2CI-2, 2C-T-2, 5-MeO-DiPT, PMMA, GHB, ketamine) through the 
EWS to the national focal points, Europol, the European Commission and the European Agency 
for the Evaluation of Medicinal Products in accordance with article 3 of the EU joint action.
Analysing and providing standardised feedback on the progress reports from the national focal 
points submitted in the framework of the Reitox joint action core task was also undertaken.
A joint information note from the EMCDDA and Europol, describing the presence of a number of 
new substances on the EU market and which had been monitored by the EMCDDA and Europol, 
was submitted to the Horizontal Working Party on Drugs of the Council of the European Union in 
October 2002. 
An analysis of the conceptual and technical framework for setting up the EMCDDA’s information 
system on synthetic drugs (database/website) was carried out and a first prototype created and 
tested. 
The programme participated in the evaluation of the joint action as foreseen in the EU action 
plan, providing all relevant information and documentation to the evaluator.
A training course for the candidate countries took place on 15 to 16 April on the setting up of 
their national early-warning systems on new synthetic drugs.
A training course on the functioning of the joint action was organised in Slovenia in the 
framework of the Reitox Academy training programme piloted by the Phare Project on 
EMCDDA—CEECs cooperation and was attended by the future EWS correspondents to the 
EMCDDA from 11 candidate countries to the EU. It was carried out by EMCDDA staff as well as 
experts from the Greek and Luxembourg Reitox focal points, the Dutch Ministry of Justice, the UK 
and the Commission. The focus of the course was preparing the launch of the Reitox joint action 
core task in all candidate countries with a special emphasis on the joint action’s EWS. 
A second technical workshop on the joint action’s EWS on new synthetic drugs was run on 26 
November with the purpose of strengthening the Reitox network’s capacity for the EWS and 
enhancing the EMCDDA’s coordination in it. The workshop was attended by EWS correspondents 
from the EU and candidate-country focal points, as well as members of the Scientific Committee, 
representatives from Europol, the European Commission and other experts. In particular, four 
items were discussed: communication and information flows between key EWS players; the 
importance of integrating networks; the relevance of a proactive approach; and the availability 
of reference materials on new synthetic drugs. The workshop resulted in a number of proposals 
to improve the system generally and to tackle these issues. These were presented to the Reitox 
meeting on 27 November.
Article 4 JA 
Meetings of the Scientific Committee’s Subcommittee on the joint action on new synthetic drugs of 
4 April and 12 December 2002, focused on:
a)  the further development of the Guidelines for the risk assessment of new synthetic drugs.
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A decision was taken on the validation exercise of the mechanism for estimating and weighting 
the risk-assessment criteria by using MDMA as the possible benchmarking substance.  On 
taking into account the Scientific Committee members’ final scoring results of the exercise, it was 
decided that this method has shown not to be an appropriate tool to be used in the frame of the 
joint action’s risk assessments. However, the Guidelines for risk assessment should remain subject 
to further development as these constitute an organic set of formulae to be modified in line with 
new experience and additional knowledge. 
b)  improvement of the implementation of the joint action 
The members discussed three items related to improving the implementation of the joint action: 
availability of reference samples, anticipation of new synthetic drugs and amnesty bins analysis 
as an additional information source for detecting new synthetic drugs. They agreed that these 
items will be further discussed in 2003 in order to achieve healthy progress.
Outputs
Reports
•  Conclusions of the Council’s Horizontal Working Party on Drugs on the monitoring of GHB and 
ketamine on the basis of the EMCDDA/Europol progress report on this monitoring (Cordrogue 
24)
•  ‘Joint information from EMCDDA and Europol to the Horizontal Working Party on Drugs of 
the Council of the European Union in the framework of the joint action on new synthetic drugs’ 
(Cordrogue 94)
•  ‘Report on the risk assessment of PMMA in the framework of the joint action on new synthetic 
drugs’
•  ‘Early-warning system on new synthetic drugs: Guidance on implementation’
•  Working group document on the improvement of the joint action’s EWS following the EMCDDA 
workshop on the EWS on NSD of 26 November 2002
Publications
•  ‘Report on the risk assessment of PMMA in the framework of the joint action on new synthetic 
drugs’
•  ‘Early-warning system on new synthetic drugs: Guidance on implementation’
News release 
Council decision of 28 February 2002 defining PMMA as a new synthetic drug to be subject to 
control measures and criminal penalties in all EU Member States (OJ L 63/14, 6.3.2002) 
For further information on the joint action see: 
http://www.emcdda.eu.int/policy_law/joint_action.shtml
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Monitoring national and Community strategies and their 
impact 
(Strategies and impact analysis, programme P4)
Overview of main achievements
The year 2002 has been marked by consolidating the work that was already implemented by 
P4 in the areas of: public expenditure (where we are still in the phase of conceptualisation); 
coordination and strategies (production of the report on national strategies and coordination); 
legal database (fine-tuning and improvement of data presented in the ELDD and insertion of data 
from candidates countries); legal analysis, both at national and European levels (production of 
three comparative studies on ‘medicinal cannabis and its derivatives’, ‘the role of the quantity in 
the prosecution of drug users’ and ‘drugs and driving’); and of participating in the monitoring 
and evaluation process of the EU action plan on drugs (offline and online publication of the 
‘Baseline 1999’ snapshot exercise, and contribution to the Commission’s communication on 
the mid-term evaluation of the EU action plan). A considerable amount of work of collecting, 
monitoring and analysing the existing EU and EC legal framework and instruments on drugs 
was also accomplished and will certainly become one of the major activities of P4 in the years to 
come.
P4 has also started to feed and lead profound strategic reflection on the scientific methods and 
tools that could be relevant, feasible and useful for contributing to the monitoring, the analysis 
and the evaluation of national strategies and policies in the drugs field in the EU and of the EU 
action plan on drugs. As a step towards achieving this, it has started to develop internal scientific 
cooperation with other EMCDDA programmes (and tried to initiate external cooperation) and 
exchange of expertise with the P4 Scientific sub-Committee, scientific and research communities, 
etc.
Projects
The different areas covered by the programme are separated into projects and are under the 
responsibility of a project manager.
Drug legislation
Objectives
•  To maintain and fine-tune information sources for the European Legal Database on Drugs 
(ELDD)
•  To produce internally a series of comparative analyses on key issues to publish in the ELDD
•  To expand the ELDD to EU law
•  To assess translation costs
•  To improve the quality of data presented in the ELDD (set up links, write abstracts, check the 
language)
•  To establish methodology and requirements for the collection of drug laws within candidate 
countries
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•  To start inserting data from candidates countries into the ELDD 
•  To bring ELDD to a wider audience in order to disseminate legal and policy information
•  To monitor and evaluate the impact of the ELDD promotion strategy
Activities
A Legal Correspondent network was established in the candidate countries. The annual meeting 
of Legal Correspondents took place in Lisbon. A promotional campaign for ELDD was launched 
which is being monitored on an ongoing basis. The feasibility of linking ELDD to EU law was 
assessed as were the costs for translating ELDD.
Outputs
•  Publication of three comparative studies on ELDD
•  Five candidate countries published on ELDD
•  Summaries of national information on precursor legislation published
•  Contribution to chapter 2 of the 2002 Annual report 
•  Contribution to the briefing Drugs in focus – ‘Drug users and the law’
For further information see: http://eldd.emcdda.eu.int
National drug strategies
Objectives 
National drug strategies:
•  To describe EU Member States’ strategies and coordination arrangements on drugs as a basis 
for assessment and analysis
•  To increase awareness on strategic approaches to drug policies
•  To identify methodology to assess the impact of national drug strategies (pm)
Public expenditure on drugs:
•  To increase awareness on the cost of public policies and interventions in the field of drugs
•  To assess and fine-tune methodology to estimate public expenditure in the field of drugs
Activities
The year 2002 has been marked by the production of the report on national strategies and 
coordination, the finalisation of the report on public expenditure in the EU and the launching of 
its follow-up activities, as well as the contribution to other reports and publications of the Centre. 
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During the first semester the briefing Drugs in focus – ‘Drug users and the law’ and number 5 in 
the Insights series Prosecution of drug users in the EU were edited and published. At the same 
time visits were undertaken to the EU countries to collect data and information for processing into 
the report on ‘National strategies and coordination’. The latter, which responds to the request of 
the EU action plan on drugs, was presented at the meeting of the drug coordinators in December 
and will form the basis for further work at EU level. 
In the public expenditure field, work undertaken has concentrated on fine-tuning the Kopp report, 
presented at the EMCDDA in September, and identifying follow-up measures. Two new initiatives 
have been undertaken in this line: a modelling test in selected countries with the collaboration 
of Professor Peter Reuter, and a feasibility study in the area of direct expenditure with Professor 
Kopp.
Outputs
•  EMCDDA Insights number 5: Prosecution of drug users in the EU (for executive summary see
http://www.emcdda.eu.int/multimedia/publications/insights/prosecution_executive_
summary.pdf)
•  EMCDDA briefing Drugs in focus – ‘Drug users and the law’
•  Report: Public expenditure on drugs in the EU
•  Report: National strategies and coordination in the field of drugs in the European Union 
•  Contribution to chapter 2 of the 2002 Annual report
European legal instruments on drugs
Objectives
•  To collect, monitor and analyse the existing EU and EC legal framework and instruments on 
drugs
•  To analyse the information map on the judicial process and prosecution and conviction statistics 
•  To review definitions, data availability and a possible indicator for prosecution of drug users in 
the EU
Activities
Several working papers were drawn up in the year: on the European legal instruments on drugs; 
on the EU ‘acquis’ on drugs; on the possibilities to extend the ELDD to European law; on the legal 
basis of the other European agencies; on the budget lines of the external action of the EC in the 
fight against drugs; and on the report of the European Parliament on the EU action plan (2000–
2004). An EMCDDA paper on network cooperation was also co-drafted. A presentation note on 
the implementation of the EU action plan on drugs/Baseline 1999 snapshot was also written.
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Outputs
•  Draft report on the information map concerning the judicial process, prosecution statistics and 
conviction statistics
EU action plan – focus on evaluation
Objectives 
•  To contribute to the establishment of a baseline for the EU action plan on drugs (2000–2004)
•  To contribute to the mid-term evaluation of the EU action plan on drugs (2000–2004)
•  To support the evaluation of the EU action plan
Activities
Activities in this area can be summed up as follows:
•  contribution to the 2002 updating of the ‘Scoreboard’ of the Commission;
•  contribution to the Commission’s communication on mid-term evaluation of the EU action plan 
on drugs.
Outputs 
•  Offline and online publication of the ‘Baseline 1999’ snapshot (Cordrogue  72)
For further information see:
http://snapshot.emcdda.eu.int and http://www.emcdda.eu.int/policy_law/eu.shtml
Reitox and Enlargement
Overview of main achievements
In January 2002, the final report of the external evaluation of the Reitox focal points and their 
contribution to the EMCDDA objectives and results was presented to the Management Board. 
The latter created a working group to advise the Executive Director of the EMCDDA in the 
preparation of a new operating framework for the Reitox system. The working group document, 
which was welcomed by the heads of focal points and by the Management Board, was later 
transformed into a shorter paper describing the Reitox operating framework and the EMCDDA’s 
participation in the financing of the focal points, which, in the future, will be based on a grant 
system. A final Management Board decision on the new operating framework was expected in 
January 2003.
Meetings of heads of focal points took place in February, June and November 2002. Further to 
a Bureau decision of March 2002, the coordinators of the 13 candidate countries national focal 
points are invited to attend all regular Reitox meetings. So far, this increase from 16 to 29 focal 
points has not created any operational problems. 
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The negotiations for ‘EMCDDA membership’ between the Commission and the 13 candidate 
countries to the European Union were launched in March 2002; first ‘EMCDDA memberships’ 
are expected in 2003. At the end of September 2002, the Phare project ‘Cooperation 
EMCDDA—CEECs’ was completed successfully. The new Phare project ‘Participation of the 
candidate CEECs in the EMCDDA’ started in November 2002. Its main objective is to make the 
national focal points of the ten candidate CEECs increasingly operational and to contribute to the 
implementation of the EMCDDA work programme.
The actions foreseen in the 2002 work programme were successfully completed. They mainly 
concerned: participating actively in the follow-up of the evaluation of the national focal points; 
animating the Reitox network and improving communication among the different partners; 
organising meetings and training activities (heads of focal points, working group on the follow-
up of the external evaluation, training and conferences with the candidate countries, as well as 
the working group on guidelines); executing the ‘core tasks’ contracts; further harmonising the 
EMCDDA requests to focal points, as well as exercising quality control on the inputs from focal 
points and providing feedback to them. 
The main achievements of the Phare Project ‘Cooperation EMCDDA—CEECs’ include: National 
Action Plans for the development of Drug Information Systems in the CEECs (NAPDIS), National 
reports from the CEECs, the 2002 Report on the drug situation in the candidate CEECs and the 
launch of the Reitox Academy. The coordinators of the focal points of Cyprus, Malta and Turkey 
participated in heads of focal points and Reitox Academy seminars. The EMCDDA carried out an 
assessment mission to these three countries.
Reitox
Reitox data and information quality and improvement
Objectives 
•  To complete the definition of a feedback mechanism for the Reitox tasks
•  To improve data quality and comparability of the national reports and other national focal 
point outputs
•  To provide feedback on key epidemiological indicators
Activities
The mechanism for improving the quality of data concerning the Reitox core tasks was further 
developed and implemented. Individual meetings with each national focal point as well as 
cluster meetings with groups of national focal points took place on data quality and related 
organisational aspects. The reporting guidelines for the national reports were harmonised.  
Permanent contact has been established with national focal points on reporting guidelines and on 
ways to improve the national reports. A working group with four focal points on the guidelines 
for the 2003 national reports was set up.
Outputs
•  Document on data quality and networking functionality
•  Feedback on national reports and standard tables, including input from the Scientific 
Committee
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•  Minutes of the working group on guidelines for 2003 national reports
•  Guidelines for 2003 national reports, including selected issues and new standard tables
For further information on Reitox see: http://www.emcdda.eu.int/partners/reitox.shtml
Reitox network management
Objectives
•  To animate and manage the network of the Reitox national focal points, thereby assuring the 
main partnership between the EMCDDA and the EU Member States as regards the collection 
and dissemination of drugs data and information
•  To improve and revise the current Reitox system on the basis of the outcome of the external 
evaluation and its related working group’s activities (including a revised contractual 
relationship between the EMCDDA and the Reitox national focal points)
•  To improve and further develop the animation and management issues of the network generally 
(including the revision of the private Reitox extranet)
Activities
Network animation
The Reitox network ‘waking state’ interface was animated and networking policies and strategies 
formulated. Coordination and support was provided to the focal points to assist them in achieving 
their activities for the EMCDDA.
Network’s functionality development and improvement
The network’s operating framework was developed and much work carried out on devising a 
suitable revised contractual relationship with the national focal points. The network’s technical 
and content-related aspects were improved, notably through the further development of the 
private Reitox extranet.
Follow-up was provided for Reitox core activities through: communicating on reports and 
information delivery; the internal dissemination of the Reitox activities and results; the 
coordination of the EMCDDA information flow and requests to the national focal points; and 
managing and following up the financial and contractual aspects of the Reitox contracts.
Internal liaison and consultation involved coordinating the communications between the national 
focal points and EMCDDA staff involved; consulting with EMCDDA staff regarding national focal 
points activities and subsequent results and participating in the integration of candidate countries’ 
focal points into the network.
Outputs
•  Draft ‘Operating framework for the Reitox system’ (to be adopted by the Management Board)
•  Draft grant agreement with national focal points (to be adopted by the Management Board)
•  Revised private Reitox extranet (both structure and content-related)
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•  Working documents and minutes of the 23rd, 24th and 25th Reitox heads of focal points 
meetings
•  Working documents and minutes of the Reitox external evaluation working group
Enlargement
Cooperation with candidate countries (includes the implementation of the Phare—EMCDDA 
project)
Objectives 
•  To develop further the technical assistance project with the CEEC candidate countries 
•  To prepare the integration of the candidate countries in the activities of the EMCDDA
•  To support and to start a cooperation project with Cyprus, Malta and Turkey
•  To further develop the assessment methodology into an EU tool for assessment in third countries
•  To develop the concept of a Reitox Academy and to prepare a draft business plan (including 
modules, profile of clients and operational costs)
Activities
The technical assistance project has been implemented successfully in all candidate CEECs, and 
was extended until the end of September 2002. An external evaluation and an external audit 
have been conducted and they provided useful recommendations for further improvements. A 
new contract with the Phare programme was signed at the end of November 2002.
All candidate CEECs have been progressively integrated into the activities of the Centre, covering 
all departments, with a priority given to the five key epidemiological indicators, to the ELDD and 
to the joint action on new synthetic drugs.
Cyprus, Malta and Turkey have been systematically invited to all meetings and training activities. 
Assessment exercises have been carried out using the same reference framework, and twinning 
projects are under preparation.
The assessment methodology used was presented and discussed in a joint meeting with DG 
AIDCO, and the first draft of a future publication is in preparation. A future Reitox Academy 
certification programme is under consideration, in cooperation with the European Commission.
The Reitox Academy was organised and implemented with the participation of Reitox national 
focal points both as trainers and trainees. A curriculum was prepared, including different training 
modules (Foundation course, Intensive courses, Specialised courses, Certification course). All 
training activities have been evaluated.
Outputs
•  10 national focal points appointed
•  13 assessment reports
•  13 country profiles and scoreboard 
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•  10 draft National Action Plans on Drug Information Systems (NAPDIS)
•  7 national reports 
•  2002 Annual report on the drug situation in candidate CEECs
•  Methodological handbook on the joint action on new synthetic drugs
•  5 national training activities
•  Final activity report to the EC (and quarterly, inception and intermediary reports)
•  External evaluation report and financial audit report
•  Reitox Academy: 7 sessions, 1 CD-ROM with the training materials and 1 new semi-public 
website
For further information on the candidate countries see: http://candidates.emcdda.eu.int/
Communication and dissemination
Offline publications
Objectives
•  To produce printed publications, addressing the most important aspects of the drugs 
phenomenon in the EU and Norway and the candidate CEECs
•  To produce a printed publication reflecting the main results and achievements of the EMCDDA 
in 2002
•  To publish the EMCDDA budget in the EU official journal
•  To produce publications in the framework of the joint action 
•  To consolidate and improve the EMCDDA specialised series – Monographs, Insights and 
Manuals
•  To provide a high-quality editorial service
Activities 
The 2002 Annual report on the state of the drugs problem in the European Union and Norway 
was published in the 11 EU languages – be it late in Dutch due to initial complications in the 
translation and production process – and also in Norwegian. A particular effort was made to 
improve the structure and presentation of the report in order to render the information more 
accessible to the reader. An expanded online version in 12 languages was also prepared with 
supplementary graphics, references and statistical tables.
The first Annual report on the drug situation in the candidate CEECs was also edited and 
produced.
In 2002, the EMCDDA published its General report of activities 2001; one title in its Insights 
series and two Risk assessment reports. A further Risk assessment report is in its final stages of 
production.
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Increasingly the website is used for the dissemination of project reports and summaries and an 
extensive amount of time was spent on editing such material for online dissemination. 
In May, the EMCDDA organised and hosted a working group on editing with representatives 
from five European agencies. The aim was to share practical experiences of editing procedures, 
to discuss how problems are currently dealt with and to identify shortcomings/pitfalls so that 
training needs could be established. Joint training activities are to be followed up in 2003. 
Outputs
•  2002 Annual report on the state of the drugs problem in the European Union and Norway
•  2002 Annual report on the drug situation in the candidate CEECs
•  General report of activities 2001
•  EMCDDA budget 2002
•  Prosecution of drug users in Europe – varying pathways to similar objectives (Insights 5)
•  Risk assessment reports on GHB and ketamine
•  25 edited technical reports and executive summaries
Details of all the EMCDDA’s publications can be found at: http://www.emcdda.eu.int/infopoint/
publications.shtml
Online publications
Objectives
•  To devise a common strategy and development plan for online publications at the EMCDDA
•  To improve the Content Management Application (CMA)
•  To further develop the public website
•  To produce the 2002 Annual report online 
•  To function as a central interface for integrating existing projects into the overall online 
dissemination strategy, as well as for issues on development – the European Legal Database on 
Drugs (ELDD), EDDRA, Reitox and Enlargement, EIB, QED and Intranet
•  To develop a prototype for an online Inventory of synthetic drugs and a joint action website
Activities
A new version of the online publication strategy in 2002 made the original version of spring 
2000 obsolete.
The most visible accomplishment during the current year is the change of the general website 
layout which was launched in June on the central website http://www.emcdda.eu.int 
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Special websites for the Management Board and for the snapshot project were also produced. 
The new layout was applied to other EMCDDA websites – QED and the ELDD. Work on the 
Content Management Application was carried out to simplify the interface.
Throughout the year people looking for extensive material on the drugs phenomenon turned to 
the EMCDDA’s 2001 online edition of the Annual report on the state of the drugs problem in the 
European Union. The Centre decided to publish a complete and improved online version of the 
2002 Annual report in all eleven official EU languages plus Norwegian. 
A substantial number of activities were carried out for Enlargement. Apart from the public 2002 
Report on the drug situation in the candidate CEECs online, a special service was created – the 
Reitox Academy training programme website, where access is restricted to all national focal 
points and to all the participants in the training activities. 
The Legal Database (ELDD) served as a prototype for integrating multilingual information that is 
based on the CEEC languages and their character sets. 
Outputs
•  Online publication strategy
Online publications
•  http://www.emcdda.eu.int (among others, new design), http://annualreport.emcdda.eu.int 
(new version in 12 languages), plus  http://ar2001.emcdda.eu.int for last year’s report
•  http://eldd.emcdda.eu.int/
•  http://qed.emcdda.eu.int
•  http://cma.emcdda.org
New services/links 
•  Snapshot site http://snapshot.emcdda.eu.int
•  Management Board site: http://mboard.reitox.emcdda.eu.int
•  Prototype of new synthetic drugs information system:
http://nsd.reitox.emcdda.org and http://nsd-info.emcdda.org
•  Reitox/Enlargement: http://candidates.emcdda.eu.int, http://academy.emcdda.eu.int
Media relations and periodicals
The EMCDDA’s media relations programme is built along three axes: 
1) the distillation and proactive dissemination of news stories and quality information to the 
media; 
2) interaction with the media and the provision of appropriate response services; 
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3) impact-assessment through follow-up and the preparation of press reviews. 
The overall goal of the programme is to raise the visibility of the Centre as the European authority 
in the drugs field and to provide a high-quality information service to journalists. Tasks and 
activities in 2002 were conceived in line with the EMCDDA Dissemination and Communication 
Strategy and Action Plan, which regard the media as an important conduit of information from 
the EMCDDA to policy-makers and the general public. 
Objectives 
•  To produce, on a regular basis, the EMCDDA’s bimonthly newsletter Drugnet Europe as an 
informative, news channel from the Centre
•  To produce, on a regular basis, a new series of bimonthly EMCDDA Policy briefings, in line 
with the EMCDDA’s Dissemination and Communication Strategy, thereby offering a tailor-made 
product to the Centre’s primary target group (policy-makers)
•  To prepare media-friendly information in line with the EMCDDA’s Dissemination and 
Communication Strategy; promote EMCDDA products in the media; and increase media 
contacts
•  To organise EMCDDA press events, including a Media day for the launch of the Annual report 
on the state of the drugs problem in the European Union and Norway and the Report on the 
drug situation in the candidate CEECs
•  To prepare press reviews as a follow-up and impact-assessment exercise of the Centre’s press 
actions
•  To improve the image of the EMCDDA media products/materials in line with the new EMCDDA 
corporate identity project.
Activities
In 2002, Drugnet Europe was released on a bimonthly basis. A new Spanish version brought the 
total number of languages up to five. A new series of bimonthly policy briefings, Drugs in focus, 
was launched in January 2002 and was produced in 12 languages. 
Thirteen news releases were produced during the year and disseminated to journalists throughout 
Europe and other world regions. These focused on new EMCDDA product launches and key 
visits/events. Promotional mailings were also sent out to journalists on release of new EMCDDA 
products. 
Journalist contacts increased in 2002, partly on account of a new registration function in the 
News and media services section of the website. This section of the website was updated in 
2002. It is designed as a dynamic and useful online service for journalists and contains the 
EMCDDA’s media-targeted products: news releases, special features articles, photos, images, 
quote bank, and registration possibilities. In the run-up to the launch of the 2002 Annual report, 
the Centre updated existing media contacts with the help of the Reitox network.
On 26 June, International Day Against Drug Abuse and Illicit Drug Trafficking, the EMCDDA 
organised a press breakfast for Lisbon-based Portuguese and foreign media. The theme of the 
event was HIV/AIDS. A ‘Media day’ was organised on 3 October launching the 2002 Annual 
report on the state of the drugs problem in the European Union and Norway and the Report on 
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the drug situation in the candidate CEECs. This consisted of a European launch of the reports to 
the media at a news conference at the European Parliament (Brussels); presentations to a core 
group of drug-specialised journalists; and the intensive dissemination of the report’s findings 
throughout the EU and further afield. 
Four internal press reviews were produced in 2002 to measure the impact of the EMCDDA’s 
interaction with the media. An Annual report press review was prepared following the launch. 
Throughout the year, the EMCDDA’s media helpdesk provided the daily service of responding to 
journalists’ requests. Design work was concluded in the autumn for a range of press materials 
under the Corporate Identity project. These will be launched in 2003.
Outputs
•  Drugnet Europe (6 editions in ES, DE, EN, FR, PT).
•  Drugs in focus (6 editions in 11 EU languages plus Norwegian).
•  13 news releases
•  4 quarterly press reviews
•  1 Annual report press review 
For further information on EMCDDA media relations see: http://www.emcdda.eu.int/infopoint/
news_media.shtml 
Dissemination and communication related activities
Objectives
•  To complete the EMCDDA Corporate Identity project
•  To draw up guidelines for the implementation of these new visual communication rules
•  To increase multilingualism in EMCDDA products (particularly the more ‘synthesised 
information’)
•  To develop strategic policy in the area of marketing in order to raise the profile of the agency 
and to draw the maximum input from each EMCDDA product
•  To create a new set of marketing products following completion of the Corporate Identity 
project
•  To market the EMCDDA and its work via fairs, exhibitions
Activities
In 2002, the EMCDDA completed a Corporate Identity project launched in September 2001. The 
project culminated in the production of an EMCDDA Corporate Identity Manual and CD-ROM 
which sets out communication rules for the agency, as well as framework designs and templates 
for all EMCDDA products. Staff guidelines were drawn up at the end of the year prior to the 
launch of the new image in January 2003 to ensure maximum implementation. 
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In line with the EMCDDA Dissemination and Communication Strategy, the agency’s multilingual 
output increased in 2002, particularly with regard to synthesised materials. The Annual report 
was published in 12 languages (11 EU + Norwegian) as was a new series of briefings for policy-
makers. The EMCDDA newsletter Drugnet Europe was produced for the first time in Spanish, 
bringing the total number of languages to five. Lengthier scientific reports were published in 
English only.
Marketing proposals relating to the European Legal Database on Drugs (ELDD) and EMCDDA 
staff on mission were concluded in the first half of 2002, while an EMCDDA marketing strategy 
was drawn up at the end of the year for discussion in the Management Board. In addition, a 
full set of marketing products was designed in the framework of the Corporate Identity project 
for production in 2003. All EMCDDA products were promoted via its website and newsletter 
and new publications were presented to book reviewers at scientific journals via promotional 
mailings. The agency did not participate in the Frankfurt Book fair and Online Information 2002 
for budgetary reasons.
Outputs
•  EMCDDA Corporate Identity Manual and CD-ROM 
•  EMCDDA Corporate Identity staff guidelines
•  EMCDDA Marketing strategy
•  Marketing action plan, ELDD
•  Marketing action plan, EMCDDA staff on mission
•  Promotional mailings
Distribution and information 
Objectives
•  To ensure a permanent and rational distribution of the EMCDDA publications 
•  To ensure management of contact addresses from EMCDDA bodies, partners and targeted 
audiences
•  To coordinate lists of key policy-makers in the EU Member States for the distribution of products 
such as policy briefings
•  To manage stock and back-stock of EMCDDA publications and to monitor stock at EUR-OP
•  To supply background information on the Centre’s activities to European citizens
Activities
The distribution of new publications was coordinated and managed and dispatches to external 
conferences were made on request. Mailing lists were updated and subscriptions to publications 
logged. Print-run quantities were assessed for new publications in line with demand. Levels of 
stocks were monitored and invoices processed. Responses were provided to requests on a daily 
basis.
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Outputs
•  List of EMCDDA mailing lists (up to 3 000 addresses and 45 000 subscriptions)
•  List of policy-makers by countries
•  Inventory of stock levels
•  Responses to requests
Documentation
Objectives
•  To manage the Documentation and Information Centre (DIC)
•  To provide a high-quality internal information service on drugs and drug addiction covering all 
EMCDDA working areas
•  To stimulate and support specific information needs – DSI (Dissemination of selective 
information) and to contribute to the successful completion of in-house research projects
•  To provide external users with a qualitative tool to access the EMCDDA publications and 
reports
•  To increase the visibility of the EMCDDA through making available internal publications and 
reports
•  To participate in network activities in the documentary field with national, European and 
international partners and increase the visibility of the EMCDDA and its products
Activities 
The documentary activity constitutes a permanent task and the main achievements during 2002 
focused on the following working areas:
Management of the Documentation and Information Centre: The processing of documentation 
involved the selection, acquisition, cataloguing and dissemination of information. Services 
dedicated to staff included bibliographies and the dissemination of publications. Bibliodatabase 
(Library Catalogue) was further developed. An exploratory study was carried out and proposal 
drawn up for the software migration of Bibliodatabase from StatusIQ to Microsoft SQL server, 
and from WinLib to WinLIB2000, in order to implement a better performing version. 
Information requests from external and scientific audiences were dealt with. Working documents 
relating to documentation as well as to the framework of internal cooperation activities were 
prepared. A User’s Guide containing the documentary procedures and guidelines adopted by the 
DIC was drawn up and the archives room organised.
European cooperation activities: Participation in the development of the ‘ELISAD Gateway’ 
project continued and working documents were prepared for this project. The ‘Lisbon Gateway’ 
meeting was organised and held from 6 to 8 February at the EMCDDA headquarters. Following 
this meeting the Centre’s involvement and cooperation were detailed and a ‘cooperation 
agreement’ between both organisations established.
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Outputs
•  Production of a monthly Journal, with the table of contents of the EMCDDA’s serials collection 
•  Compilation of a User’s Guide containing the documentary procedures and guidelines adopted 
by the DIC
For further information on EMCDDA documentation activities see
http://oxford.emcdda.org/winlib/index.html and 
http://www.emcdda.eu.int/infopoint/library_resources/serials.shtml
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Supporting activities
Administrative support
Overview of main achievements
Attention focused on continuing to implement the relevant measures of the EMCDDA reform. This 
entailed in particular:
•  the refinement of instruments and procedures for planning, monitoring, implementing and 
reporting the work of the EMCDDA and the allocation/use of its resources;
•  the implementation of the EMCDDA strategy for human resources; and
•  the assessment of the EMCDDA’s present and expected needs in terms of real estate 
infrastructure and the solutions available to cope with the inadequacy of the working space 
provided by the current premises of the Centre in Lisbon.
Human and material resources
Objectives 
•  To implement the internal reform process in the area of human resources, to ensure the daily 
management of human resources and to continue implementation of the EMCDDA’s human 
resources policy as adopted by the Management Board in 2001
•  To ensure the daily management of the material resources
Activities and outputs
During the year in question, a number of key posts were filled (Head of P4, Head of P1). In order 
to facilitate inter-institutional mobility and provide the opportunity for temporary staff to become 
permanent officials, an internal competition was organised at the Centre. Four permanent posts 
were filled (and seven staff members were placed on a waiting list pending the creation of further 
permanent posts).
A paper on equality of opportunities was prepared for implementation in 2003.
In the area of material resources, the effective daily management of the EMCDDA’s material 
resources was assured.
Financial and accounting management 
In 2002, key financial decisions taken by the EMCDDA Management Board included: a decision 
to offer the Director discharge on the implementation of the 2000 budget; the adoption of the 
2002 budget of € 9 412 500; and the adoption of the EMCDDA’s 2003 preliminary draft budget 
of € 9 998 256.
The budgetary figure for 2002 are presented in the tables that follow.
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Budgetary provisions and appropriations, 2002
Title Description EUR
1 Expenditure relating to persons working with the office
Staff in active employment 4 947 602
§ Other staff-related expenditure (exchange of officials, etc ) 42 000
Total under Title 1 4 989 602
2 Buildings, equipment and sundry operating expenditure
Investment in immovable property, rental of buildings and associated costs 289 800
Data processing 425 425
Movable property and associated costs 145 640
Current administrative expenditure+ Postal charges and telecommunications 226 425
Socio-medical infrastructure 41 955
Total under Title 2 1 129 245
3 Expenditure resulting from special functions carried out by the institution
Statutory meetings 270 000
Expenditure on formal and others meetings +Representative expenses 330 465
Studies, surveys, consultations 174 500
Publishing 806 404
European Network on Drugs and Drug Addiction Reitox 1 500 000
Missions 212 284
Total under Title 3 3 293 653
Total core budget 9 412 500
4 Expenditure relating to other subsidies
EC financing of specific projects
PHARE financing for implementing pre-accession strategy 943 861
10 Other expenses (reserve)
Total budget 10 356 361
Execution of the budget: Credit consumption, 2002
(Commitments)
Title Description % consumption of
available credits
1 Staff
Staff salaries, allowances, etc 99.51%
2 Buildings, equipment and sundry operating expenditure 88.26%
3 Operating expenditure 98.31%
Total consumption (Titles 1, 2, 3 ) 97.74%
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EMCDDA balance sheet for the financial years 2001 and 2000 : Assets
Assets 2001 2000
Fixed assets
(3 781 687.70) 3 827 537.75
• Buildings 2 950 000.00
• Installation and furniture 150 956.85
• Vehicles 46 784.56
• Information Technology 633 946.29
• Depreciation 94 –2001 -557 194.96
• Surplus value 4 987.98
Stocks
• Office equipment 10 467.53 11 725.96
Current assets
• Grant to be received from EC 36 350.00 36 350.00
• Specific grants to be received 38 589.33 100 684.82
• VAT to be recovered from Portugal 27 796.97 3 026.03
• Sundry debtors 37 771.88 43 465.28
• Payments on specific subsidies 1 951.96 1 318.24
Cash accounts
• Banks 3 925 420.54 4 372 401.77
• Imprest account 53.26 4 000.00
Total assets 7 307 882.19 8 400 509.85
EMCDDA balance sheet for the financial years 2001 and 2000: Liabilities
Liabilities 2001 2000
Fixed capital
∞ Own capital 3 792 155.23 3 839
263.71
∞ Balance for the financial year 82 046.89 2 075 607.24
∞ Grant to be received from EC 36 350.00 36 350.00
Current liabilities
∞ Specific grants (to be paid) 38 589.33 100 684.82
∞ VAT to be paid from Portugal 27 796.97 3 026.02
∞ Sundry creditors 44 242.21 38 954.02
∞ Earmarked revenue Phare 640 767.34
∞ Earmarked revenue Tser 43 086.74
∞ Revenue collected to be reused 46 460.31
∞ Regulatory carry-over provision 2 185 426.59 1 960 301.05
∞ Budgetary authority carry-over provision 270 300.00 233 579.98
∞ Re-use accounts 100 660.58 112 743.00
Total liabilities 7 307 882.19 8 400 509.85
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Out-turn account
Revenue and expenditure for the financial years 2001 and 2000
Revenue 2001 2000
• European Commission grant 8 750 000.00 8 213 650.00
• Norway grant 398 750.00
• Bank interest 99 192.41
• Phare EC grant – earmarked revenue 1 056 139.00
• Tser project – earmarked revenue EC 77 722.67
• Carry-over revenue from 2000 – Tser project 6 347.84
Total revenue EC grant + Norway + Bank interest (A) 9 247 942.41 8 213 650.00
Total revenue (EC grant + Norway + Phare) 10 204 889.00
Total revenue 10 400 468.74
Expenditure
• Title 1: Staff expenditure
– Payments 4 026 978.36 3 875 935.14
– Automatic carry-overs on title 1-C8-2002 311 090.49 112 433.87
– Non-automatic carry-overs on title 1-C2-2002 116 626.00 76 630.99
• Title 2: Buildings, equipment and miscellaneous administrative
expenditure
– Payments 560 480.83 681 771.48
– Automatic carry-overs on title 2-C8-2002 571 915.17 339 659.43
– Non-automatic carry-overs on title 2-C2-2002 24 427.00 13 569.09
• Title 3: Operating expenditure
– Payments 1 882 740.07 1 498 412.35
– Automatic carry-overs on title 3-C8-2002 1 302 420.93 1 508 207.75
– Non-automatic carry-overs on title 3-C2-2002 129 247.00 143 379.90
• Title 1/2/3-RO: Phare
– Payments 415 372.46 -
– Automatic carry-overs on title 3-C8-2002 640 766.60 -
• Title 4-RO: Tser project
– Payments 40 983.77 -
– Automatic carry-over on title 4-RO-2002 43 086.74 -
• Title 4-RO: SocexDrug
– Payments 12 950.94 -
Total expenditure Title 1/2/3 + automatic and non automatic carry-
over (B)
8 925 925.85
Total expenditure Title 1/2/3/4/earmarked rev. automatic and non
automatic carry-over
1 153 160.51 8 250 000.00
Total Expenditure 10 079 086.36
Out-turn for the financial year 
• Balance of 2001 –(A)-(B) 322 016.15 495 148.10
• Cancelled appropriations 319 272.49
• Depreciation 94–2000 -516 821.50
• Depreciation 2001 -40 373.46
• Extraordinary balance -2 047.20
• Balance carried over from the previous year 0 2 075 607.24
Balance for the financial year 82 046.89 2 075 607.24
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Planning and evaluation
Objectives 
•  To ensure the management and development of the EMCDDA tools for planning, monitoring, 
reporting and evaluation
•  To assure technical support to the management of internal coordination 
•  To provide in-house legal assistance and advice, particularly with regard to the revision of the 
EMCDDA financial rules
Activities
The EMCDDA project-based instruments and procedures for planning, monitoring, reporting 
and assessing the work of the Centre were consolidated in accordance with the activity based 
management (ABM) and activity based budgeting (ABB) principles.
Further measures to decentralise internal management were prepared and implemented in order 
to improve the execution of the EMCDDA work programme. These measures build on the existing 
project-based planning and reporting system, focusing on the achievement of objectives and 
results, while developing evaluation procedures.
The project manager also participates in the inter-Agencies working party, chaired by the 
European Commission’s services, aimed at contributing to the preparation of the new framework 
financial regulation for the EC Agencies, in accordance with the new financial rules applicable to 
the EC budget.
Outputs
•  EMCDDA work programme and action plan for 2002, budget 2002 (published in the EU 
Official Journal), draft work programme 2003, draft budget 2003, preliminary draft budget 
2004
•  Quarterly reports on the implementation of the programmes and projects of the EMCDDA 
2002 work programme
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Information technology
Overview of main achievements
2002 was a year concentrating on infrastructure. Following a situation of severe understaffing in 
2001, a sound basis for defining and starting the implementation of a medium-term strategy for 
the IT team and the IT infrastructure needed to be established.
The most important projects in keywords were: the snapshot website; the new EMCDDA public 
website; Annual report online; deployment of a central database server; several security and 
network performance upgrades; change of Internet services provider; preparation for staff to 
access email boxes from extra-muros; upgrade of system providing network file shares; CD-ROM 
system image for user desktops; and revamp of the data centre layout.
The programme pertaining to stabilising IT staffing started in autumn 2001 was a key element 
to the success of the ongoing work. In parallel, in the context of the infrastructure stabilisation 
programme, competencies are being developed in every core IT area.  
Electronic dissemination systems and IT advice projects
Objectives 
•  To ensure a very high level of reliability, and the appropriate development of the functionality 
of the EMCDDA electronic dissemination systems
•  To plan appropriately the future development of all online products
•  To improve the functionality of the software systems in use
•  To assure the technical maintenance of the websites WWW, ELDD, VLIB, Annual report online, 
EIB, Intranet, Reitox, QED
•  To provide continuous project advice on WWW, ELDD, EDDRA, VLIB, Annual report online, 
WINLIB, EIB, Intranet, Reitox, QED
•  To investigate and prepare the integration of additional projects
•  To maintain the Unix server 
Activities
The new Unix server ‘Nottingham’ was integrated. Research was carried out on Apache web 
server software and its integration into ColdFusion environment and, similarly, on IPlanet Web 
Server 6, and a comparison of results was made. Subsequently a life environment for Apache 
was set up. Groupware was also investigated.
Special components were developed for a central authentication for different projects and 
similar horizontal modules were developed to be used across several projects. Bugs in externally 
developed projects, such as ELDD, were fixed.
Project advice was provided to several projects, for example, to the Reitox/Enlargement team in 
the preparation of the tender for the website of the candidate countries’ report.
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Research was carried out on software development methodology and project management 
approaches for software-related projects.
A project inventory document for online projects at the EMCDDA was prepared, which was 
used by the Internal Management Coordination Committee (IMCC) as a basis for prioritising 
development tasks for 2002/2003.
Outputs
•  New web services for Management Board, Snapshot and other projects on the new server 
‘Nottingham’, which covers both server maintenance and new project integration
•  Priority document for the IMCC 
New services/links: http://snapshot.emcdda.eu.int, http://candidates.emcdda.eu.int and
http://mboard.reitox.emcdda.eu.int, http://academy.emcdda.eu.int, 
Networking and Internet security
Objectives
•  To ensure a very high level of reliability and functionality of the EMCDDA networking 
components
•  To conceptualise the integration of the new office into the network
•  To ensure a very high level of reliability and functionality of access to Internet and other 
networks
•  To improve data security
•  To improve data protection
•  To improve protection against aggressive viruses
Activities
A new Antivirus server was set up at the firewall level and an upgrade made of the firewall 
software. The network was migrated to a new Internet Service Provider in order to obtain better 
service. Cooperation was provided on the question of a new office building and re-arrangement 
of the server room and network settings, integration of new racks and network equipment were 
carried out.
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Management activities
Statutory bodies and executive management
Management Board
Activities and main decisions
At the 23rd meeting of the Management Board in Lisbon on 16 to 18 January, the Board 
adopted amongst others: the 2002 work programme; the Scientific Committee’s work 
programme; the General report of activities 2001; a budget of € 9 412 500 for 2002; a 
preliminary draft budget of € 9 998 256 for 2003; a carry-over of € 270 000 from the year 
2001 to 2002; a part of the implementing rules related to staff matters; and elected Mrs Magistris 
and Mrs Garzon as members of the Bureau. The Board also gave discharge to the Director 
for the implementation of the 2001 budget. It further discussed UNDCP annual reporting, the 
external evaluation of the Reitox network, the five key indicators and the cooperation with the 
European Commission in this field, and the EMCDDA’s external relations. The Board was also 
informed of the main decisions/discussions in the Bureau and the main EMCDDA activities.
At the 24th meeting of 3 to 5 July, the Board decided to forward for the next Management Board 
meeting a more detailed paper concerning Reitox and to opt for a grant based system of up to 
€ 110 000 per Member State. It also decided to modify the guidelines for national reports to 
enable data needed for the UNDCP ARQ to be directly extracted and reported by the Member 
States and endorsed the draft addendum to the Memorandum of Understanding between the 
EMCDDA and UNDCP. Amongst other issues the Board also designated Mr B. De Ruyver and 
Mr Y. Bisiou as additional members to the Scientific Committee, took note of the paper on the 
implementation progress and perspectives on the five key indicators, took note of the state of play 
of the 2002 Annual report and decided on the approach for the structure of the 2003 Annual 
report, gave mandate to the Bureau to discuss the reflection paper on the role of the EMCDDA/
European Commission and Management Board, approved the proposed procedure as regards 
the building and decided to launch the new corporate identity image during the Board’s next 
meeting. The Danish delegation presented the elements of their Presidency Programme which 
were relevant for the EMCDDA. 
Bureau
Activities and main decisions
In 2002, the Bureau met four times in Lisbon, once in Brussels (1).
At its meeting of 16 January 2002, the Bureau prepared the meeting of the Management 
Board of 16 to 18 January. It adopted a document estimating the impact of Enlargement on 
the EMCDDA and its work, and agreed that after receiving comments by members of the 
Management Board, the Chair and the Director would decide upon the new corporate identity for 
the Centre. The Bureau also supported the extension of the terms of reference of the Budgetary 
Committee.
At its meeting of 27 March, the Bureau discussed the draft action plan for the implementation of 
the 2002 work programme. The Bureau took note of the state of play of the work of the Reitox 
(1) 16 January (Lisbon), 27 March (Lisbon), 17 May (Lisbon), 3 October (Brussels) and 4 December (Lisbon).
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working group and agreed that the candidate countries could participate in this working group 
from June onwards. It further agreed on the procedure for selecting additional members of the 
Scientific Committee.
At its meeting of 17 May, the Bureau mainly discussed the document from the Reitox working 
group which presented different options regarding the grant system to the national focal 
points, and prepared the Management Board meeting in July. The Bureau welcomed the first 
quarterly report on the implementation of the work programme and expressed support for the 
decentralisation plan. Furthermore, it agreed on the structure of the 2002 Annual report and 
commented on the production process of the 2003 Annual report. The issue of the building was 
examined, and the Bureau welcomed the interim solution proposed by the EMCDDA to relocate 
some of the staff to a building nearby the Centre until a new building was found.
The Bureau discussed in depth at its meeting on 3 October the summary paper required by 
the Management Board in July on the framework for the functioning of the Reitox system and 
asked for revisions. Further to the decision taken by the Management Board to introduce a grant 
system for the EMCDDA’s participation in the financing of the national focal points, the Bureau 
commented on the draft contract for grant agreement prepared by the EMCDDA in collaboration 
with the European Commission, which should be approved by the Management Board. It was 
decided that the Bureau would comment by written procedure on the role of the EMCDDA and 
new medium-term perspectives and discuss the issue in a further meeting. Concerning the real 
estate issue, the Bureau saw the necessity to visit some buildings short listed by the EMCDDA. 
The production schedule of the 2003 Annual report was approved. The Bureau took note of the 
second quarterly report on the work programme implementation.
The meeting of 4 December was given to discussing the role of the EMCDDA and new medium-
term perspectives, to visiting buildings in Lisbon and taking a decision on this issue, and to 
preparing the January Management Board meeting. 
Scientific Committee
Activities, main discussion points and results 
At the 17th meeting of the Scientific Committee from 4 to 5 April 2002, progress reports were 
presented on the external evaluation of the Reitox focal points as well as on the implementation 
process of the next EU framework research programme (2002—2006).
During this session, the thematic subcommittees of the Scientific Committee, set up in accordance 
with its work plan for the period 2001–2003, convened for the first time. The four subcommittees 
– corresponding to the Centre’s main working areas – concentrated on the work to be carried out 
by each subcommittee in view of providing a clear input to the scientific targets of the Centre’s 
work programme. 
Following this meeting, and with the purpose of assisting the EMCDDA in guaranteeing 
the scientific quality of the Centre’s Annual report, the committee provided feedback on the 
information to be used in the 2002 and 2003 draft Annual reports. The committee was also 
invited to provide comments on the EMCDDA’s template for the evaluation of the 2002 national 
reports and on the draft 2003 national reporting guidelines and standard tables.
The EMCDDA’s Scientific Committee held its 18th meeting in Lisbon from 12–13 December and 
gave a positive opinion on the Centre’s 2003 draft work programme. 
General report of activities 2002
70   71  
The Committee welcomed both of its roles in quality assurance of the work of the national focal 
points at national level and at European level within the Centre. 
The Committee also discussed the achievements of the Centre in 2002. Additionally, it analysed 
within its subcommittees the different actions foreseen by all projects for 2003.
Finally, the members acknowledged the work that has been achieved by the EMCDDA’s 
operational programmes, despite the fact that there were limited human and financial resources 
available. 
Internal communication and quality management
Internal communication
Objectives
With the personnel of the EMCDDA now numbering about 70, an organised framework 
for internal communication has become an important issue, in order to facilitate the flow 
of information in all directions and to avoid the risks deriving from lack of information and 
misinformation. The internal communication effort ensures that the different levels of the 
organisation and the officials involved are able to share their views in order to better cooperate 
in achieving the EMCDDA’s objectives.
Activities 
The Internal Communications Manager (ICM) assures the day-to-day management and 
coordination of internal communication, namely through internal publications, formal and 
informal communication fora and other means. 
Since June 2002, the ICM has made an inventory of the fields where internal communication 
could be better or where it is lacking. In June 2002, a seminar on internal communication 
allowed a definition of the subject to be drawn up and identified the areas for new and better 
internal communication.
A Common Information System (SIC) is now available to manage online the missions, 
the holidays and all the administrative information about the employees. It was set up in 
collaboration with the Administration and Training Department.
Attention has also focused on internal security information where rules and training are being 
drawn up.
The day-to-day internal information made available to staff is coordinated by the ICM in 
collaboration with all departments. In particular, this includes publishing online news updates and 
making available internal working documents. The ICM is also closely involved in the process of 
decentralisation. 
An internal newsletter is in preparation which will be available both in electronic and printed 
form. Work on redesigning the Intranet is also being carried out.
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Chapter 1
Quality management
Objectives 
The EMCDDA sets out five objectives along the way to total quality:
•  user satisfaction;
•  product quality;
•  development of the Reitox network;
•  staff satisfaction; and
•  in-house productivity.
The Quality Management policy will offer everyone – management and staff, at their individual 
levels of responsibility – a series of tools to enable them to achieve these objectives.
Activities
In 2002, quality management focused on implementing a training programme to reinforce staff’s 
management skills with courses organised for the whole of the office on project management, 
conflict management and time management. 
An internal course on managing quality improvement projects was held and attended by 15 
volunteers. Furthermore, a targeted course on human resource management tools was organised 
for the department concerned.
The quality manager participated in the facilitation of a new appraisal system adopted by the 
Commission and organised an internal course on how to carry out appraisals for all evaluators.
Outputs
A number of projects are in the pipeline and about to yield first results:
•  a quality model – combining elements of the Australian Quality Model and various public 
sector models – will be proposed to the IMCC before the end of 2002 and implemented in the 
coming year;
•  a web-based training course on quality management in English, French and Portuguese was 
made available to all EMCDDA staff;
•  work has commenced on helping one of our focal points to achieve certification – a move 
which will hopefully encourage other focal points to follow.
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Chapter 4
Cooperation with EU bodies and international partners
Institutional liaison
European Parliament
In 2002, the EMCDDA followed discussions in the European Parliament regarding the EU drug 
phenomenon. On 2 October, the Centre presented its 2002 Annual report to the Committee on 
Citizens’ Freedoms and Rights, Justice and Home Affairs prior to its official launch on 3 October 
at the European Parliament.
Council of the European Union
The EMCDDA participated as an expert body, along with Europol, in all meetings of the 
Horizontal Working Party on Drugs (HWPD) of the Council of the European Union as well as in 
the preparatory meetings at the request of the Presidency. The main achievements include: the 
adoption by the Council on 28 February of a decision to place under control the new synthetic 
drug PMMA; the presentation to the HWPD by EMCDDA and Europol of a Joint report on the 
one-year monitoring of GHB and ketamine undertaken in 2001 at the request of the Council 
and of a Joint information note on a number of new synthetic drugs which were detected in the 
European Union. 
The EMCDDA also participated in the meetings of national drug coordinators organised by 
the Spanish Presidency in Salamanca and by the Danish Presidency in Brussels. At the Brussels 
meeting, the EMCDDA presented its study on Strategies and coordination in the field of drugs in 
the European Union undertaken with the cooperation of the European Commission.
European Commission 
The EMCDDA pursued close cooperation with various Directorates of the European Commission:  
•  Drugs Coordination Unit, Directorate-General for Justice and Home Affairs: cooperation in 
exploring the best ways to support implementation of the five key epidemiological indicators in 
Member States. The EMCDDA participated actively in the preparation of the Communication 
from the Commission to the Council and the European Parliament on the mid-term evaluation 
of the EU action plan on drugs (2000–2004) and delivered to the Commission with the support 
of its focal points and Europol a baseline for the EU action plan on drugs.
•  Directorate-General for Health and Consumer Protection: contribution to the committee of the 
Community action programme for the prevention of drug dependence and to the preparation 
of the drug-related aspects of the draft 2003 work programme of the programme of 
Community action in the field of Public Health (2003–2008). 
•  Directorate-General for Research: the EMCDDA cooperated in the follow-up to the DG RTD 
workshop on the priorities for drug-related research (VI Framework Programme). It also 
participated in the call for expressions of interest to identify research actions for specific 
programme topics as a basis for preparing the work programmes of the VI Framework 
Programme. Presentations were made by DG RTD at the two EMCDDA Scientific Committee 
meetings on the objectives and instruments of. 
•  Eurostat: the EMCDDA cooperated closely on the topic of drug-related deaths. Eurostat 
participated in the working group on the five key indicators.
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European Union agencies
The EMCDDA participated in several meetings of the EU decentralised agencies. 
International cooperation
Objectives 
•  To establish cooperation mechanisms with the relevant partners at international level 
•  To provide support to the EMCDDA Executive Director regarding external activities 
Activities
A revision to the terms of the Memorandum of Understanding (MoU) between the UNDCP and 
the EMCDDA was made, identifying a number of concrete cooperation activities relating to P1, 
P2, P3 and P4 activities. A signing ceremony between the UNDCP and EMCDDA Executive 
Directors took place in Vienna on 3 July 2002.
EMCDDA officials attended a number of important international meetings:
•  Plan Nacional sobre Drogas, on 9 January 2002, Madrid;
•  45th UNDCP Commission of Narcotic Drugs, from 11 to 15 March 2002, Vienna;
•  Airports Group of the Council of Europe, from 10 to 12 April 2002, Madrid;
•  Interpol Legal Service Director on 5 April 2002, Lisbon;
•  Pompidou Group Permanent Correspondent meeting on 18 and 19 April 2002, Strasbourg;
•  CICAD 31st Regular Session, from 23 to 26 April 2002, Washington;
•  Meeting with EC TAXUD DG on 25 June 2002, Brussels;
•  CICAD 32nd Regular Session, from 2 to 6 December 2002, Mexico;
•  Pompidou Group Permanent Correspondent meeting from 11 to 13 December 2002, 
Strasbourg.
Outputs
•  Addendum and Annex to the MoU between UNDCP and EMCDDA.
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
is one of the decentralised agencies set up by the European Union to carry
out specialised technical or scientific work.
Its role is to gather, analyse and disseminate ‘objective, reliable and
comparable information’ on drugs and drug addiction and, in doing so,
provide its audiences with a sound and evidence-based picture of the drug
phenomenon at European level.
Among the Centre’s target groups are policy-makers who use this
information to help formulate coherent national and Community drug
strategies. Also served are professionals and researchers working in the
drugs field and, more broadly, the European media and general public.
EMCDDA website: http://www.emcdda.eu.int
